U.S. patent application number 10/462326 was filed with the patent office on 2004-01-01 for substituted cyclic compounds, preparation method and pharmaceutical compositions containing them.
Invention is credited to Bennejean, Caroline, Delagrange, Philippe, Guillaumet, Gerald, Klupsch, Frederique, Langlois, Michel, Lesieur, Daniel, Renard, Pierre, Viaud, Marie-Claude.
Application Number | 20040002490 10/462326 |
Document ID | / |
Family ID | 9526252 |
Filed Date | 2004-01-01 |
United States Patent
Application |
20040002490 |
Kind Code |
A1 |
Lesieur, Daniel ; et
al. |
January 1, 2004 |
Substituted cyclic compounds, preparation method and pharmaceutical
compositions containing them
Abstract
The invention concerns compounds of formula (I): R-A-R' wherein:
A is as defined in the description; R represent a group (V), (VI),
(VII), or (VIII), where E, Q, R.sup.1, R.sup.2, R.sup.3, v and
R.sup.4 are as defined in the description; R' represents a
--(CH.sub.2).sub.t--R.sup.5 group wherein t and R.sup.5 are as
defined in the description, and medicaments containing the same.
1
Inventors: |
Lesieur, Daniel;
(Gondecourt, FR) ; Klupsch, Frederique; (Hulluch,
FR) ; Guillaumet, Gerald; (Saint Jean Le Blanc,
FR) ; Viaud, Marie-Claude; (Tours, FR) ;
Langlois, Michel; (Sceaux, FR) ; Bennejean,
Caroline; (Charenton Le Pont, FR) ; Renard,
Pierre; (Le Chesnay, FR) ; Delagrange, Philippe;
(Issy Les Moulineaux, FR) |
Correspondence
Address: |
THE FIRM OF HUESCHEN AND SAGE
500 COLUMBIA PLAZA
350 EAST MICHIGAN AVENUE
KALAMAZOO
MI
49007
US
|
Family ID: |
9526252 |
Appl. No.: |
10/462326 |
Filed: |
June 16, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10462326 |
Jun 16, 2003 |
|
|
|
09700056 |
Nov 10, 2000 |
|
|
|
6605632 |
|
|
|
|
09700056 |
Nov 10, 2000 |
|
|
|
PCT/FR99/01101 |
May 10, 1999 |
|
|
|
Current U.S.
Class: |
514/224.2 ;
514/230.5; 514/248; 514/249; 514/300; 514/301; 514/302; 544/105;
544/353; 544/47; 546/113; 546/114; 546/115 |
Current CPC
Class: |
C07C 233/65 20130101;
C07C 271/20 20130101; C07D 471/04 20130101; C07D 221/10 20130101;
C07C 2602/10 20170501; A61P 35/00 20180101; C07C 323/62 20130101;
C07D 405/12 20130101; C04B 35/632 20130101; C07D 335/06 20130101;
A61P 3/06 20180101; C07D 405/06 20130101; C07D 319/18 20130101;
C07D 249/08 20130101; A61P 3/10 20180101; C07D 213/70 20130101;
C07C 233/62 20130101; C07D 401/12 20130101; A61P 25/04 20180101;
A61P 25/16 20180101; A61P 25/18 20180101; C07D 233/42 20130101;
C07C 2601/02 20170501; C07D 235/06 20130101; C07D 311/58 20130101;
C07D 333/20 20130101; C07D 311/60 20130101; C07D 233/84 20130101;
A61P 15/08 20180101; C07D 491/04 20130101; A61P 25/08 20180101;
A61P 25/22 20180101; C07C 275/24 20130101; C07D 231/12 20130101;
A61P 25/20 20180101; C07D 207/27 20130101; A61P 43/00 20180101;
C07D 307/81 20130101; C07D 333/38 20130101; C07D 407/12 20130101;
A61P 25/00 20180101; C07D 209/14 20130101; C07D 307/92 20130101;
A61P 1/00 20180101; C07D 495/04 20130101; C07D 319/20 20130101;
C07D 333/58 20130101; A61P 9/00 20180101; A61P 25/06 20180101; C07C
2602/08 20170501; C07D 335/08 20130101; C07D 333/74 20130101; C07D
209/20 20130101; C07C 2601/14 20170501; A61P 5/02 20180101; C07D
495/14 20130101; A61P 25/28 20180101; C07D 209/60 20130101; A61P
25/24 20180101; C07C 233/43 20130101; C07C 237/48 20130101; C07D
233/56 20130101; C07D 261/20 20130101 |
Class at
Publication: |
514/224.2 ;
514/230.5; 514/248; 514/249; 514/300; 514/301; 514/302; 544/47;
544/105; 544/353; 546/113; 546/114; 546/115 |
International
Class: |
A61K 031/542; A61K
031/538; A61K 031/502; A61K 031/498; A61K 031/4745 |
Foreign Application Data
Date |
Code |
Application Number |
May 12, 1998 |
FR |
98.05957 |
Claims
We claim:
1. A compound of formula (I): R-A-R' (I) wherein .diamond-solid. A
represents a ring system of formula (II): 51 wherein X represents
oxygen, sulphur or nitrogen or C(H).sub.q (wherein q is 0, 1 or 2)
or NR.sub.0 (wherein R.sub.0 represents hydrogen, linear or
branched (C.sub.1-C.sub.6)alkyl, aryl, aryl-(C.sub.1-C.sub.6)alkyl
in which the alkyl moiety is linear or branched) or SO.sub.2Ph, Y
represents nitrogen or C(H).sub.q (wherein q is 0, 1 or 2), Z
represents nitrogen or C(H).sub.q (wherein q is 0, 1 or 2), but X,
Y and Z cannot represent three hetero atoms simultaneously, B
represents a benzene or pyridine nucleus, the symbol .... means
that the bonds may be single or double, it being understood that
the valency of the atoms is respected, wherein R substitutes the
ring B and R' substitutes the ring containing X, Y and Z, or R and
R' substitute the ring B, a ring system of formula (III) 52 wherein
X' represents oxygen or sulphur or C(H).sub.q (wherein q is 0, 1 or
2), Y' represents C(H).sub.q (wherein q is 0, 1 or 2) or NR.sub.0
wherein R.sub.0 is as defined hereinbefore, Z' represents
C(H).sub.q (wherein q is 0, 1 or 2) or NR.sub.0 wherein R.sub.0 is
as defined hereinbefore, T' represents oxygen or sulphur or
C(H).sub.q (wherein q is 0, 1 or 2), it being understood that, when
Y' or Z' represents a hetero atom, the other three variables ((X',
Z', T') and (X', Y', T'), respectively) cannot represent a hetero
atom, the symbol .... is as defined hereinbefore, B' represents:
benzene, naphthalene when X', Y', Z' and T' do not simultaneously
represent C(H).sub.q (wherein q is 0, 1 or 2), or pyridine when X'
and T' simultaneously represent C(H).sub.q (wherein q is 0, 1 or
2), wherein R substitutes the ring B' and R' substitutes the ring
containing X', Y', Z' and T', or R and R' substitute the ring B', a
ring system of formula (IV): 53 representing the ring systems
(IV.sub.a-d) 54 wherein n is an integer such that
0.ltoreq.n.ltoreq.3, W represents oxygen, sulphur or nitrogen, or
[C(H).sub.q].sub.p (wherein q is 0, 1 or 2, and p is 1 or 2) or
NR.sub.0 wherein R.sub.0 is as defined hereinbefore, the symbol
.... is as defined hereinbefore, wherein R' substitutes the ring 55
and R substitutes one or other of the two other rings, or biphenyl
wherein R substitutes one of the benzene rings and R' substitutes
the other, or R and R' substitute the same benzene ring, it being
understood that the ring systems of formulae (II), (III) and (IV)
and the biphenyl group may be unsubstituted or substituted (in
addition to the substituents R and R') by from 1 to 6 radicals,
which may be the same or different, selected from R.sub.a,
OR.sub.a, COR.sub.a, COOR.sub.a, OCOR.sub.a, OSO.sub.2CF.sub.3 and
halogen, wherein R.sub.a represents hydrogen, unsubstituted or
substituted linear or branched (C.sub.1-C.sub.6)alkyl,
unsubstituted or substituted linear or branched
(C.sub.2-C.sub.6)alkenyl, unsubstituted or substituted linear or
branched (C.sub.2-C.sub.6)alkynyl, linear or branched
(C.sub.1-C.sub.6)polyhaloalkyl, unsubstituted or substituted
(C.sub.3-C.sub.8)cycloalkyl, unsubstituted or substituted
(C.sub.3-C.sub.8)cycloalkyl-(C.sub.1-C.sub.6)alkyl in which the
alkyl group is linear or branched, unsubstituted or substituted
(C.sub.3-C.sub.8)cycloalkenyl, unsubstituted or substituted
(C.sub.3-C.sub.8)cycloalkenyl-(C.sub.1-C.sub.6)alkyl in which the
alkyl group is linear or branched, aryl,
aryl-(C.sub.1-C.sub.6)alkyl in which the alkyl moiety is linear or
branched, aryl-(C.sub.1-C.sub.6)alkenyl in which the alkenyl moiety
is linear or branched, heteroaryl,
heteroaryl-(C.sub.1-C.sub.6)alkyl in which the alkyl moiety is
linear or branched, heteroaryl-(C.sub.1-C.sub.6)alkenyl in which
the alkenyl moiety is linear or branched, unsubstituted or
substituted linear or branched (C.sub.1-C.sub.6)heterocycloalkyl,
unsubstituted or substituted heterocycloalkenyl, substituted or
unsubstituted heterocycloalkyl-(C.sub.- 1-C.sub.6)alkyl in which
the alkyl moiety is linear or branched, or substituted or
unsubstituted heterocycloalkenyl-(C.sub.1-C.sub.6)alkyl in which
the alkyl moiety is linear or branched, .diamond-solid. R
represents: a group of formula (V): 56 wherein Q represents sulphur
or oxygen, R.sup.1 represents NR'.sub.aR".sub.a or OR.sup.1.sub.a
(wherein R'.sub.a and R".sub.a, which may be the same or different,
may take any of the values of R.sub.a and may also form, together
with the nitrogen atom carrying them, a 5- to 10-membered cyclic
group which may contain, in addition to the nitrogen atom by which
it is linked, from one to three hetero atoms selected from oxygen,
sulphur and nitrogen, and R.sup.1.sub.a may take any of the values
of R.sub.a except for the hydrogen atom), a group of formula (VI):
57 wherein R.sup.2 represents R.sub.a as defined hereinbefore,
R.sup.3 represents COR'.sub.a, CSR'.sub.a, CONR'.sub.aR".sub.a,
CSNR'.sub.aR".sub.a, COOR'.sub.a, CSOR'.sub.a or S(O).sub.vR'.sub.a
(wherein R'.sub.a and R".sub.a, which may be the same or different,
are as defined hereinbefore and may also form, together with the
nitrogen atom carrying them, a cyclic group as defined
hereinbefore, and v is 1 or 2), a group of formula (VII): 58
wherein v is as defined hereinbefore and R.sup.4 represents
NR'.sub.aR".sub.a, NR.sub.aCOR'.sub.a, NR.sub.aCSR'.sub.a,
NR.sub.aCONR'.sub.aR".sub.a, NR.sub.aCSNR'.sub.aR".sub.a or
NR.sub.aCOOR'.sub.a, wherein R.sub.a, R'.sub.a and R".sub.a are as
defined hereinbefore, or, when A represents a ring system of
formula (II) or (III) or biphenyl, forms, together with two
adjacent carbon atoms of the cyclic structure A carrying it, a ring
of formula (VIII): 59 the ring formed containing from 5 to 7 atoms
and it being possible for the said ring to contain from 1 to 3
hetero atoms selected from nitrogen, sulphur and oxygen, and one or
more unsaturations, and being optionally substituted by one or more
radicals, which may be the same or different, selected from
R.sub.a, OR.sub.a, COR.sub.a, COOR.sub.a, OCOR.sub.a,
NR'.sub.aR".sub.a, NR.sub.aCOR'.sub.a CONR'.sub.aR".sub.a, cyano,
oxo, SR.sub.a, S(O)R.sub.a, SO.sub.2R.sub.a, CSR.sub.a,
NR.sub.aCSR'.sub.a, CSNR'.sub.aR".sub.a,
NR.sub.aCONR'.sub.aR".sub.a NR.sub.aCSNR'.sub.aR".su- b.a and
halogen, wherein R.sub.a, R'.sub.a and R".sub.a, which may be the
same or different, are as defined hereinbefore and R'.sub.a and
R".sub.a may also form, together with the nitrogen atom carrying
them, a cyclic group as defined hereinbefore, .diamond-solid. and
R' represents a group of formula (IX): -G-R.sup.5 (IX) wherein G
represents an alkylene chain --(CH.sub.2).sub.t-- (wherein t is an
integer such that 0.ltoreq.t.ltoreq.4 when A represents a tricyclic
structure and such that 1.ltoreq.t.ltoreq.4 when A represents a
bicyclic structure), optionally substituted by one or more
radicals, which may be the same or different, selected from
R.sub.a, OR.sub.a, COOR.sub.a, COR.sub.a (in which R.sub.a is as
defined hereinbefore) or halogen, and R.sup.5 represents 60 wherein
Q, R.sub.a, R'.sub.a and R".sub.a (which may be the same or
different) are as defined hereinbefore, it being possible for
R'.sub.a and R".sub.a to form, together with the nitrogen atom
carrying them, a cyclic group as defined hereinbefore, it being
understood that: "heterocycloalkyl" is taken to mean any saturated
mono- or poly-cyclic group containing from 5 to 10 atoms containing
from 1 to 3 hetero atoms selected from nitrogen, oxygen and
sulphur, "heterocycloalkenyl" is taken to mean any non-aromatic
mono- or poly-cyclic group containing one or more unsaturations,
containing from 5 to 10 atoms and which may contain from 1 to 3
hetero atoms selected from nitrogen, oxygen and sulphur, the term
"substituted" used in respect of the expressions "alkyl", "alkenyl"
and "alkynyl" indicates that the groups in question are substituted
by one or more radicals, which may be the same or different,
selected from hydroxy, linear or branched (C.sub.1-C.sub.6)alkoxy,
linear or branched (C.sub.1-C.sub.6)alkyl, linear or branched
(C.sub.1-C.sub.6)polyhaloalkyl- , amino and halogen, the term
"substituted" used in respect of the expressions "cycloalkyl",
"cycloalkylalkyl", "cycloalkenyl", "cycloalkenylalkyl",
"heterocycloalkyl", "heterocycloalkenyl", "hetero-cycloalkylalkyl"
and "heterocycloalkenylalkyl" indicates that the cyclic moiety of
the groups in question is substituted by one or more radicals,
which may be the same or different, selected from hydroxy, linear
or branched (C.sub.1-C.sub.6)alkoxy, linear or branched
(C.sub.1-C.sub.6)alkyl, linear or branched
(C.sub.1-C.sub.6)polyhaloalkyl- , amino and halogen, "aryl" is
taken to mean any aromatic, mono- or poly-cyclic group containing
from 6 to 22 carbon atoms, and also the biphenyl group,
"heteroaryl" is taken to mean any aromatic mono- or poly-cyclic
group containing from 5 to 10 atoms containing from 1 to 3 hetero
atoms selected from nitrogen, oxygen and sulphur, it being possible
for the "aryl" and "heteroaryl" groups to be substituted by one or
more radicals, which may be the same or different, selected from
hydroxy, linear or branched (C.sub.1-C.sub.6)alkoxy, linear or
branched (C.sub.1-C.sub.6)alkyl, linear or branched
(C.sub.1-C.sub.6)polyhaloalkyl- , cyano, carboxy, nitro, amino and
halogen, 10 it being understood that: when A represents indole,
there cannot be any substituents in the 2-position, when A
represents indole and R represents --NHCOR.sub.'.sub.a,
--NHCOOR'.sub.a or NHCONR'.sub.aR".sub.a, then G-R.sup.5 cannot
represent --(CH.sub.2).sub.2--NHCOR.sub.b wherein R.sub.b
represents (C.sub.1-C.sub.4)alkyl or CF.sub.3, when A represents
benzofuran or benzothiophene, there cannot be any COPh (wherein Ph
is substituted or unsubstituted) in the 2-position, when A
represents benzofuran or benzothiophene, R cannot represent
--NR.sub.aCOR.sub.c, --NHSO.sub.2R.sub.c, --NHCOCH.sub.2R.sub.c, or
NHCONHR.sub.c, wherein R.sub.c represents heterocyclic or aryl,
when A represents tetrahydronaphthalene, R.sup.5 cannot represent
CONR'.sub.aR".sub.a, when A represents hydrocarbon ring system and
R.sup.5 represents NHCOR'.sub.a, then R cannot represent
COOR'.sub.a, the compound of formula (I) cannot represent:
N-{8-[(acetylamino)methyl]-2-naphthyl}-2-methylpropanamide,
N-(2-{5-[(4-ethoxyanilino)sulphonyl]-1H-indol-3-yl}ethyl)acetamide,
8-[(acetylamino)methyl]-N-isopropyl-2-naphthamide, its enantiomers
and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
2. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (II'): 61wherein B, X and the
symbol .... are as defined in claim 1, its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
3. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III'): 62wherein B', X', T'
and the symbol .... are as defined in claim 1, its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
4. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (II') substituted in the
5-position by R as defined in claim 1 and in the 3-position by R'
as defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
5. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III') substituted in the
7-position by R as defined in claim 1 and in the 1- or 2-position
by R' as defined in claim 1, its enantiomers and diastereoisomers,
and addition salts thereof with a pharmaceutically acceptable acid
or base.
6. A compound of formula (I) according to claim 1, wherein R
represents a group of formula (V), its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
7. A compound of formula (I) according to claim 1, wherein R
represents a group of formula (VI), its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
8. A compound of formula (I) according to claim 1, wherein R
represents a group of formula (VII), its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
9. A compound of formula (I) according to claim 1, wherein R
represents a group of formula (V) wherein Q represents oxygen and
R.sup.1 represents NR'.sub.aR".sub.a as defined in claim 1, its
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
10. A compound of formula (I) according to claim 1, wherein R
represents a group of formula (V) wherein Q represents oxygen and
R.sup.1 represents OR.sup.1.sub.a as defined in claim 1, its
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
11. A compound of formula (I) according to claim 1, wherein R
represents a group of formula (VI) wherein R.sup.3 represents
COR'.sub.a wherein R'.sub.a is as defined in claim 1, its
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
12. A compound of formula (I) according to claim 1, wherein R
represents a group of formula (VI) wherein R.sup.3 represents
COOR'.sub.a wherein R'.sub.a is as defined in claim 1, its
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
13. A compound of formula (I) according to claim 1, wherein R
represents a group of formula (VII) wherein v is 2 and R.sup.4
represents NR'.sub.aNR".sub.a, its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
14. A compound of formula (I) according to claim 1, wherein R'
represents G-R.sup.5 wherein G represents an unsubstituted or
substituted alkylene chain --(CH.sub.2).sub.t-- wherein t is 2 or 3
and R.sup.5 represents 63wherein R.sub.a, R'.sub.ta, R".sub.a and Q
are as defined in claim 1, its enantiomers and diastereoisomers,
and addition salts thereof with a pharmaceutically acceptable acid
or base.
15. A compound of formula (I) according to claim 1, wherein R'
represents G-R.sup.5 wherein G represents an alkylene chain
--(CH.sub.2).sub.t-- wherein t is 2 or 3 and R.sup.5 represents
--NHCOR'.sub.a or --CONHR'.sub.a wherein R'.sub.a is as defined in
claim 1, its enantiomers and diastereoisomers, and addition salts
thereof with a pharmaceutically acceptable acid or base.
16. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (II') and R represents a group
of formula (V), its enantiomers and diastereoisomers, and addition
salts thereof with a pharmaceutically acceptable acid or base.
17. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (II') and R represents a group
of formula (VI), its enantiomers and diastereoisomers, and addition
salts thereof with a pharmaceutically acceptable acid or base.
18. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III') and R represents a group
of formula (VII), its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
19. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III') and R represents a group
of formula (V), its enantiomers and diastereoisomers, and addition
salts thereof with a pharmaceutically acceptable acid or base.
20. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III') and R represents a group
of formula (VI), its enantiomers and diastereoisomers, and addition
salts thereof with a pharmaceutically acceptable acid or base.
21. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III') and R represents a group
of formula (VII), its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
22. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (II') substituted in the
5-position by a group of formula (V) and in the 3-position by a
group of formula (IX), its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
23. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (II') substituted in the
5-position by a group of formula (V) and in the 3-position by a
group of formula (IX), its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
24. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (II') substituted in the
5-position by a group of formula (VII) and in the 3-position by a
group of formula (IX), its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
25. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III') substituted in the
7-position by a group of formula (V) and in the 1- or 2-position by
a group of formula (IX), its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
26. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III') substituted in the
7-position by a group of formula (VI) and in the 1- or 2-position
by a group of formula (IX), its enantiomers and diastereoisomers,
and addition salts thereof with a pharmaceutically acceptable acid
or base.
27. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III') substituted in the
7-position by a group of formula (VII) and in the 1- or 2-position
by a group of formula (IX), its enantiomers and diastereoisomers,
and addition salts thereof with a pharmaceutically acceptable acid
or base.
28. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (II'), which is substituted in
the 5-position by --CONR'.sub.aR".sub.a wherein R'.sub.a and
R".sub.a are as defined in claim 1 and substituted in the
3-position by a group of formula (IX) wherein G represents an
unsubstituted or substituted chain --(CH.sub.2).sub.t--, wherein t
is 2 or 3, and R.sup.5 represents 64wherein Q, R.sub.a, R'.sub.a
and R".sub.a are as defined in claim 1, its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
29. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (II'), which are substituted in
the 5-position by --SO.sub.2NR'.sub.aR".sub.a wherein R'.sub.a and
R".sub.a are as defined in claim 1 and substituted in the
3-position by a group of formula (IX) wherein G represents an
unsubstituted or substituted chain --(CH.sub.2).sub.t--, wherein t
is 2 or 3, and R.sup.5 represents 65wherein Q, R.sub.a, R'.sub.a
and R".sub.a are as defined in claim 1, its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
30. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (II') substituted in the
5-position by --NHCOR'.sub.a wherein R'.sub.a is as defined in
claim 1 and which is substituted in the 3-position by a group of
formula (IX) wherein G represents an unsubstituted or substituted
chain --(CH.sub.2).sub.t--, wherein t is 2 or 3, and R.sup.5
represents 66wherein Q, R.sub.a, R'.sub.a and R".sub.a are as
defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
31. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (II'), which is substituted in
the 5-position by --NHCOOR'.sub.a wherein R'.sub.a is as defined in
claim 1 and substituted in the 3-position by a group of formula
(IX) wherein G represents an unsubstituted or substituted chain
--CH.sub.2).sub.t--, wherein t is 2 or 3, and R.sup.5 represents
67wherein Q, R.sub.a, R'.sub.a and R".sub.a are as defined in claim
1, its enantiomers and diastereoisomers, and addition salts thereof
with a pharmaceutically acceptable acid or base.
32. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (II'), which is substituted in
the 5-position by COOR.sup.1.sub.a wherein R.sup.1.sub.a is as
defined in claim 1 and substituted in the 3-position by a group of
formula (IX) wherein G represents an unsubstituted or substituted
chain --(CH.sub.2).sub.t--, wherein t is 2 or 3, and R.sup.5
represents 68wherein Q, R.sub.a, R'.sub.a and R".sub.a are as
defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
33. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III'), which is substituted in
the 7-position by a group of formula --CONR'.sub.aR".sub.a wherein
R'.sub.a and R".sub.a are as defined in claim 1 and substituted in
the 1- or 2-position by a group of formula (IX) wherein G
represents an unsubstituted or substituted chain
--(CH.sub.2).sub.t--, wherein t is 2 or 3, and R.sup.5 represents
69wherein Q, R.sub.a, R'.sub.a and R".sub.a are as defined in claim
1, its enantiomers and diastereoisomers, and addition salts thereof
with a pharmaceutically acceptable acid or base.
34. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III'), which is substituted in
the 7-position by --SO.sub.2NR'.sub.aR'.sub.a wherein R'.sub.a and
R".sub.a are as defined in claim 1 and substituted in the I-- or
2-position by a group of formula (IX) wherein G represents an
unsubstituted or substituted chain --(CH.sub.2).sub.t--, wherein t
is 2 or 3, and R.sup.5 represents 70wherein Q, R.sub.a, R'.sub.a
and R".sub.a are as defined in claim 1, its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
35. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III'), which is substituted in
the 7-position by a group --NHCOR'.sub.a wherein R'.sub.a is as
defined in claim 1 and substituted in the 1- or 2-position by a
group of formula (IX) wherein G represents an unsubstituted or
substituted chain --(CH.sub.2).sub.t--, wherein t is 2 or 3, and
R.sup.5 represents 71wherein Q, R.sub.a, R'.sub.a and R".sub.a are
as defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
36. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III') substituted in the
7-position by a group --NHCOOR'.sub.a wherein R'.sub.a is as
defined in claim 1 and which is substituted in the 1- or 2-position
by a group of formula (IX) wherein G represents an unsubstituted or
substituted chain --(CH.sub.2).sub.t--, wherein t is 2 or 3, and
R.sup.5 represents 72wherein Q, R.sub.a, R'.sub.a and R".sub.a are
as defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
37. A compound of formula (I) according to claim 1, wherein A
represents a ring system of formula (III') substituted in the
7-position by a group COOR.sup.1.sub.a wherein R.sup.1.sub.a is as
defined in claim 1 and which is substituted in the 1- or 2-position
by a group of formula (IX) wherein G represents an unsubstituted or
substituted chain --(CH.sub.2).sub.t--, wherein t is 2 or 3, and
R.sup.5 represents 73wherein Q, R.sub.a, R'.sub.a and R".sub.a are
as defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
38. A compound of formula (I) according to claim 1, wherein A
represents naphthalene, dihydro- or tetrahydro-naphthalene, which
is optionally substituted (in addition to the substituents R and
R'), preferably in the 3-position, its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
39. A compound of formula (I) according to claim 1, wherein A
represents benzofuran or dihydrobenzofuran, which is optionally
substituted (in addition to the substituents R and R'), preferably
in the 2-position, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
40. A compound of formula (I) according to claim 1, wherein A
represents benzothiophene or dihydrobenzothiophene, which is
optionally substituted (in addition to the substituents R and R'),
preferably in the 2-position, its enantiomers and diastereoisomers,
and addition salts thereof with a pharmaceutically acceptable acid
or base.
41. A compound of formula (I) according to claim 1, wherein A
represents indole or indoline, which is optionally substituted (in
addition to the substituents R and R'), preferably in the
2-position, its enantiomers and diastereoisomers, and addition
salts thereof with a pharmaceutically acceptable acid or base.
42. A compound of formula (I) according to claim 1, wherein A
represents azaindole optionally substituted (in addition to the
substituents R and R'), preferably in the 2-position, its
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
43. A compound of formula (I) according to claim 1, wherein A
represents naphthalene, dihydro- or tetrahydro-naphthalene, which
is optionally substituted (in addition to the substituents R and
R') in the 3-position, substituted in the 7-position by
--NHCOR.sub.a, SO.sub.2NHR.sub.a, COOR.sup.1.sub.a or CONHR.sub.a
wherein R.sub.a and R.sup.1.sub.a are as defined in claim 1, and
substituted in the 1-position by --(CH.sub.2).sub.t--NHCOR'.sub.a
or --(CH.sub.2).sub.t--CONHR'.sub.a, wherein t is 2 or 3 and
R'.sub.a is as defined in claim 1, its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
44. A compound of formula (I) according to claim 1, wherein A
represents benzofuran or dihydrobenzofuran, which is optionally
substituted (in addition to the substituents R and R') in the
2-position, substituted in the 5-position by --NHCOR.sub.a,
SO.sub.2NHR.sub.a, COOR.sup.1.sub.a or CONHR.sub.a wherein R.sub.a
and R.sup.1.sub.a are as defined in claim 1, and substituted in the
3-position by --(CH.sub.2).sub.t--NHCOR'.sub.a or
--(CH.sub.2).sub.t--CONHR'.sub.a, wherein t is 2 or 3 and R'.sub.a
is as defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
45. A compound of formula (I) according to claim 1, wherein A
represents benzothiophene or dihydrobenzothiophene, which is
optionally substituted (in addition to the substituents R and R')
in the 2-position, substituted in the 5-position by --NHCOR.sub.a,
SO.sub.2NHR.sub.a, COOR.sup.1.sub.a or CONHR.sub.a wherein R.sub.a
and R.sup.1.sub.a are as defined in claim 1, and substituted in the
3-position by --(CH.sub.2).sub.t--NHCOR'.sub.a or
--(CH.sub.2).sub.t--CONHR'.sub.a, wherein t is 2 or 3 and R'.sub.a
is as defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
46. A compound of formula (I) according to claim 1, wherein A
represents indole or indoline, which is optionally substituted (in
addition to the substituents R and R') in the 2-position,
substituted in the 5-position by --NHCOR.sub.a, SO.sub.2NHR.sub.a,
COOR.sup.1.sub.a or CONHR.sub.a wherein R.sub.a and R.sup.1.sub.a
are as defined in claim 1, and substituted in the 3-position by
--(CH.sub.2).sub.t--NHCOR'.sub.a or
--(CH.sub.2).sub.t--CONHR'.sub.a, wherein t is 2 or 3 and R'.sub.a
is as defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
47. A compound of formula (I) according to claim 1, wherein A
represents azaindole, which is optionally substituted (in addition
to the substituents R and R') in the 2-position, substituted in the
5-position by --NHCOR.sub.a, SO.sub.2NHR.sub.a, COOR.sup.1.sub.a or
CONHR.sub.a wherein R.sub.a and R'.sub.a are as defined in claim 1,
and substituted in the 3-position by
--(CH.sub.2).sub.t--NHCOR'.sub.a or
--(CH.sub.2).sub.t--CONHR'.sub.a, wherein t is 2 or 3 and R'.sub.a
is as defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
48. A compound of formula (I) according to claim 1, wherein A
represents naphthalene, dihydronaphthalene or
tetrahydronaphthalene, which is optionally substituted (in addition
to the substituents R and R') in the 3-position, substituted in the
7-position by --NHCOOR.sub.a or 74wherein R.sub.a is as defined in
claim 1 and alk represents alkyl, and substituted in the 1-position
by --(CH.sub.2).sub.t--NHCOR'.sub.a or
--(CH.sub.2).sub.t--CONHR'.sub.a, wherein t is 2 or 3 and R'.sub.a
is as defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
49. A compound of formula (I) according to claim 1, wherein A
represents benzofuran or dihydrobenzofuran, which is optionally
substituted (in addition to the substituents R and R') in the
2-position, substituted in the 5-position by --NHCOOR.sub.a or
75wherein R.sub.a is as defined in claim 1 and alk represents
alkyl, and substituted in the 3-position by
--(CH.sub.2).sub.t--NHCOR'.sub.a or
--(CH.sub.2).sub.t--CONHR'.sub.a, wherein t is 2 or 3 and R'.sub.a
is as defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
50. A compound of formula (I) according to claim 1, wherein A
represents benzothiophene or dihydrobenzothiophene, which is
optionally substituted (in addition to the substituents R and R')
in the 2-position, substituted in the 5-position by --NHCOOR.sub.a
or 76wherein R.sub.a is as defined in claim 1 and alk represents
alkyl, and substituted in the 3-position by
--(CH.sub.2).sub.t--NHCOR'.sub.a or
--(CH.sub.2).sub.t--CONHR'.sub.a, wherein t is 2 or 3 and R'.sub.a
is as defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
51. A compound of formula (I) according to claim 1, wherein A
represents indole or indoline, which is optionally substituted (in
addition to the substituents R and R') in the 2-position,
substituted in the 5-position by --NHCOOR.sub.a or 77wherein
R.sub.a is as defined in claim 1 and alk represents alkyl, and
substituted in the 3-position by --(CH.sub.2).sub.t--NHCOR'.sub.a
or --(CH.sub.2).sub.t--CONHR'.sub.a, wherein t is 2 or 3 and
R'.sub.a is as defined in claim 1, its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
52. A compound of formula (I) according to claim 1, wherein A
represents azaindole, which is optionally substituted (in addition
to the substituents R and R') in the 2-position, substituted in the
5-position by --NHCOOR.sub.a or 78wherein R.sub.a is as defined in
claim 1 and alk represents alkyl, and substituted in the 3-position
by --(CH.sub.2).sub.t--NHCOR'.sub.a or
--(CH.sub.2).sub.t--CONHR'.sub.a, wherein t is 2 or 3 and R'.sub.a
is as defined in claim 1, its enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
53. A compound of formula (I) according to claim 1 that is
N-{2-[6-(acetylamino)-2,3-dihydro-1H-1-indenyl]ethyl}acetamide, its
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
54. Compounds of formula (I) according to claim 1 that are: methyl
3-[2-(2-furoylamino)ethyl]-1-benzofuran-5-carboxylate, methyl
3-{2-[(cyclopentylcarbonyl)amino]ethyl}-1-benzofuran-5-carboxylate,
methyl
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-1-benzofuran-5-carboxylate-
, methyl 3-[2-(3-butenoylamino)ethyl]-1-benzofuran-5-carboxylate,
methyl 3-[2-(benzoylamino)ethyl]-1-benzofuran-5-carboxylate, methyl
3-[2-(isobutylamino)ethyl]-1-benzofuran-5-carboxylate, their
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
55. Compounds of formula (I) according to claim 1 that are
N,N-diphenyl-3-[3-(acetylamino)propyl]benzo[b]furan-5-carboxamide,
3-[2-(acetylamino)ethyl]-1-benzofuran-5-carboxamide,
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-1-benzofuran-5-carboxamide,
3-[2-(2-furoylamino)ethyl]-1-benzofuran-5-carboxamide,
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-N-methyl-1-benzofuran-5-carboxami-
de, 3-[2-(acetylamino)ethyl]-N-methyl-1-benzofuran-5-carboxamide,
3-{2-[(cyclopentylcarbonyl)amino]ethyl}-N-methyl-1-benzofuran-5-carboxami-
de, 3-[2-(benzoylamino)ethyl]-N-methyl-1-benzofuran-5-carboxamide,
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-N-ethyl-1-benzofuran-5-carboxamid-
e, 3-[2-(benzoylamino)ethyl]-N-ethyl-1-benzofuran-5-carboxamide,
3-[2-(acetylamino)ethyl]-N-methyl-1-pyrrolo[2,
3-b]pyridine-5-carboxamide- ,
N-isopropyl-N-(2-propynyl)-3-[(acetylamino)methyl]-2-benzylbenzo[b]thiop-
hene-5-carboxamide,
3-[2-(benzoylamino)ethyl]-1-benzofuran-5-carboxamide, their
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
56. Compounds of formula (I) according to claim 1 that are:
N-{3-[2-(acetylamino)ethyl]-1-benzofuran-5-yl}-2,2,2-trifluoroacetamide,
N-{2-[5-(acetylamino)-1-benzofuran-3-yl]ethyl}cyclopropanecarboxamide,
N-{2-[5-(acetylamino)-1-benzothiophen-3-yl]ethyl}benzamide, their
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
57. Compounds of formula (I) according to claim 1 that are:
N-{8-[2-([2-phenylacetyl]amino)ethyl]-2-naphthyl}butanamide,
N-(8-{2-[(2-bromoacetyl)amino]ethyl}-2-naphthyl)-1-cyclohexanecarboxamide-
, N-{8-[2-(heptanoylamino)ethyl]-2,6-dinaphthyl}-2-butenamide,
N-{8-[2-(acetylamino)ethyl]-2-naphthyl}acetamide, their enantiomers
and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
58. Compounds of formula (I) according to claim 1 that are:
N-ethyl-8-{2-[(2-phenylacetyl)amino]ethyl}-2-naphthamide,
N,N-diethyl-8-{2-[2-[(cyclopropylmethyl)amino]-2-oxoethyl}-2-naphthamide,
N-phenyl-8-(2-{methyl[(propylamino)carbonyl]amino}ethyl)-2-naphthamide,
N-benzyl-1-{2-[(2,2,2-trifluoroacetyl)amino]ethyl}-2-naphthamide,
N-(2-{7-[(methylamino)carbonyl]-1-naphthyl}ethyl)-2-furamide, their
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
59. Compounds of formula (I) according to claim 1 that are:
N-{2-[7-(aminosulphonyl)-1-naphthyl]ethyl}acetamide,
N-(2-{7-[(methylamino)sulphonyl]-1-naphthyl}ethyl)acetamide,
N-(2-{7-[(methylamino)sulphonyl]-1-naphthyl}ethyl)-2-furamide,
N-(2-{7-[(ethylamino)sulphonyl]-1-naphthyl}ethyl)benzamide,
N-(2-{7-[(methylamino)sulphonyl]-1-naphthyl}ethylcyclopropanecarboxamide,
their enantiomers and diastereoisomers, and addition salts thereof
with a pharmaceutically acceptable acid or base.
60. Compounds of formula (I) according to claim 1 that are:
N-(3-{5-[(methylamino)sulphonyl]-1-benzofuran-3-yl}propyl)acetamide,
N-(2-{5-[(propylamino)sulphonyl]-1-benzofuran-3-yl}ethyl)acetamide,
N-(2-{5-[(cyclopropylamino)sulphonyl]-11-benzofuran-3-yl}ethyl)benzamide,
N-(2-{5-[(methylamino)sulphonyl]-1-benzofuran-3-yl}ethyl)-2-furamide,
N-(2-{5-[(methylamino)sulphonyl]-1-benzofuran-3-yl}ethyl)cyclopropanecarb-
oxamide,
N-(2-{2-benzyl-5-[(methylamino)sulphonyl]-1-benzothiophen-3-yl}et-
hyl)acetamide,
N-(2-{5-[(isopropylamino)sulphonyl]-1-benzothiophen-3-yl}et-
hyl)cyclopropanecarboxamide,
N-(2-{5-[(methylamino)sulphonyl]-1H-pyrrolo[2-
,3-b]pyridin-3-yl}ethyl)acetamide,
N-(2-{5-[(methylamino)sulphonyl]-1H-pyr- rolo[2,
3-b]pyridin-3-yl}ethyl)cyclopropanecarboxamide,
N-(2-{5-[(methylamino)sulphonyl]-1H-pyrrolo[2,
3-b]pyridin-3-yl}ethyl)ben- zamide,
N-(2-{5-[(methylamino)sulphonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}eth-
yl)-2-furamide, their enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
61. Compounds of formula (I) according to claim 1 that are: methyl
N-{3-[2-(acetylamino)ethyl]benzo[b]furan-5-yl}carbamate, methyl
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-1-benzofuran-5-yl-carbamate,
tert-butyl 3-[2-(acetylamino)ethyl]-1-benzofuran-5-yl-carbamate,
tert-butyl
3-[2-(acetylamino)ethyl]-1-benzofuran-5-yl-(methyl)carbamate,
methyl 3-[2-(benzoylamino)ethyl]-1-benzofuran-5-yl-carbamate,
methyl 3-[2-(isobutyrylamino)ethyl]-1-benzofuran-5-yl-carbamate,
methyl 3-[2-(2-furoylamino)ethyl]--benzofuran-5-yl-carbamate,
methyl
3-{2-[(cyclopentylcarbonyl)amino]ethyl}-1-benzofuran-5-yl-carbamate,
their enantiomers and diastereoisomers, and addition salts thereof
with a pharmaceutically acceptable acid or base.
62. A compound of formula (I) according to claim 1 that is methyl
5-[(acetylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl-carbamate,
its enantiomers and diastereoisomers, and addition salts thereof
with a pharmaceutically acceptable acid or base.
63. A compound of formula (I) according to claim 1 that is methyl
3-[(acetylamino)methyl]-3,4-dihydro-2H-chromen-6-yl-carbamate, its
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
64. A compound of formula (I) according to claim 1 that is ethyl
3-[2-(acetylamino)ethyl]-2,3-dihydro-1H-inden-5-yl-carbamate, its
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
65. Compounds of formula (I) according to claim 1 that are: methyl
3-[2-(acetylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl-carbamate,
methyl
3-[2-(2-furoylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl-carbamate,
methyl 3-[2-(benzoylamino)ethyl]-1H-pyrrolo[2,
3-b]pyridin-5-yl-carbamate- , methyl
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-1H-pyrrolo[2,3-b]pyridin--
5-yl carbamate, their enantiomers and diastereoisomers, and
addition salts thereof with a pharmaceutically acceptable acid or
base.
66. Compounds of formula (I) according to claim 1 that are: ethyl
N-(8-{2-[(2-bromoacetyl)amino]ethyl}-2-naphthyl)carbamate, methyl
N-{8-[2-(acetylamino)ethyl]-6-phenyl-2-naphthyl}carbamate, hexyl
N-{8-[2-(acetylamino)ethyl]-5,6,7,8-tetrahydro-2-naphthyl}carbamate,
methyl 8-[2-(acetylamino)ethyl]-2-naphthyl-carbamate, their
enantiomers and diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base.
67. A method for treating a living body afflicted with disorders of
the melatoninergic system comprising the step of administering to
the living body an amount of a compound of claims 1 to 66 which is
effective for the alleviation for said condition.
68. A pharmaceutical composition useful for treating melatoninergic
disorders comprising, as active principle an effective amount of a
compound as claimed in claims 1 to 66, together with one or more
pharmaceutically acceptable excipients or vehicles.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to new substituted cyclic
compounds having very valuable pharmacological characteristics in
respect of melatoninergic receptors.
DESCRIPTION OF THE PRIOR ART
[0002] The prior art discloses retroamide chain indoles substituted
by amides or carbamates for use as antagonists of GnRH (WO 9721707)
and amide chain indoles substituted by amides, carbamates or ureas
for use as antihypertensive agents (U.S. Pat. No. 4,803,218).
[0003] Retroamide chain benzofuran and benzothiophene compounds
substituted by amides or carbamates have also been described as
anti-inflammatory agents (EP 685475) or inhibitors of bone
resorption.
BACKGROUND OF THE INVENTION
[0004] In the last ten years, numerous studies have demonstrated
the major role played by melatonin (5-methoxy-N-acetyltryptamine)
in numerous physiopathological phenomena and also in the control of
circadian rhythm. Its half-life is, however, quite short owing to
its being rapidly metabolised. It is thus very useful to be able to
provide the clinician with melatonin analogues that are
metabolically more stable and that have an agonist or antagonist
character on the basis of which a therapeutic effect that is
superior to that of the hormone itself may be expected. In addition
to their beneficial action on disorders of circadian rhythm (J.
Neurosurg. 1985, 63, pp 321-341) and sleep disorders
(Psychopharmacology, 1990, 100, pp 222-226), ligands of the
melatoninergic system have valuable pharmacological properties in
respect of the central nervous system, especially anxiolytic and
antipsychotic properties (Neuropharmacology of Pineal Secretions,
1990, 8 (3-4), pp 264-2,72) and analgesic properties
(Pharmacopsychiat., 1987, 20, pp 222-223), and also for the
treatment of Parkinson's disease (J. Neurosurg. 1985, 63, pp
321-341) and Alzheimer's disease (Brain Research, 1990, 528, pp
170-174). Those compounds have also shown activity on certain
cancers (Melatonin--Clinical Perspectives, Oxford University Press,
1988, pp 164-165), ovulation (Science 1987, 227, pp 714-720),
diabetes (Clinical Endocrinology, 1986, 24, pp 359-364), and in the
treatment of obesity (International Journal of Eating Disorders,
1996, 20 (4), pp 443-446).
[0005] Those various effects take place via the intermediary of
specific melatonin receptors. Molecular biology studies have shown
the existence of a number of receptor sub-types that can bind the
hormone (Trends Pharmacol. Sci., 1995, 16, p 50; WO 97.04094). It
has been possible to locate some of those receptors and to
characterise them for different species, including mammals. In
order to be able to understand the physiological functions of those
receptors better, it is very valuable to have specific ligands
available. Moreover, by interacting selectively with one or other
of those receptors, such compounds can be excellent medicaments for
the clinician in the treatment of pathologies associated with the
melatoninergic system, some of which have been mentioned above.
[0006] In addition to the fact that the compounds of the present
invention are new, they exhibit very great affinity for melatonin
receptors and/or selectivity for one or other of the melatoninergic
receptor sub-types.
DETAILED DESCRIPTION OF THE INVENTION
[0007] More specifically, the present invention relates to
compounds of formula (I):
R-A-R' (I)
[0008] wherein
[0009] .diamond-solid. represents
[0010] a ring system of formula (II): 2
[0011] wherein
[0012] X represents an oxygen, sulphur or nitrogen atom or a group
C(H).sub.q (wherein q is 0, 1 or 2) or NR.sub.0 (wherein R.sub.0
represents a hydrogen atom, a linear or branched
(C.sub.1-C.sub.6)alkyl group, an aryl group, an
aryl-(C.sub.1-C.sub.6)alkyl group in which the alkyl moiety is
linear or branched, or SO.sub.2Ph),
[0013] Y represents a nitrogen atom or a group C(H).sub.q (wherein
q is 0, 1 or 2),
[0014] Z represents a nitrogen atom or a group C(H).sub.q (wherein
q is 0, 1 or 2), but X, Y and Z cannot represent three hetero atoms
simultaneously,
[0015] B represents a benzene or pyridine nucleus,
[0016] the symbol .... means that the bonds may be single or
double, it being understood that the valency of the atoms is
respected,
[0017] wherein R substitutes the ring B and R' substitutes the ring
containing the groups X, Y and Z, or R and R' substitute the ring
B,
[0018] a ring system of formula (III): 3
[0019] wherein
[0020] X' represents an oxygen or sulphur atom or a group
C(H).sub.q (wherein q is 0, 1 or 2),
[0021] Y' represents a group C(H).sub.q (wherein q is 0, 1 or 2) or
NR.sub.0 wherein R.sub.0 is as defined hereinbefore,
[0022] Z' represents a group C(H).sub.q (wherein q is 0, 1 or 2) or
NR.sub.0 wherein R.sub.0 is as defined hereinbefore,
[0023] T' represents an oxygen or sulphur atom or a group
C(H).sub.q (wherein q is 0, 1 or 2),
[0024] it being understood that, when Y' or Z' represents a hetero
atom, the other three variables ((X', Z', T') and (X', Y', T'),
respectively) cannot represent a hetero atom,
[0025] the symbol .... is as defined hereinbefore,
[0026] B' represents: * a benzene nucleus,
[0027] a naphthalene nucleus when X', Y', Z' and T' do not
simultaneously represent a group C(H).sub.q (wherein q is 0, 1 or
2),
[0028] or a pyridine nucleus when X' and T' simultaneously
represent a group C(H).sub.q (wherein q is 0, 1 or 2),
[0029] wherein R substitutes the ring B' and R' substitutes the
ring containing the groups X', Y', Z' and T', or R and R'
substitute the ring B',
[0030] a ring system of formula (IV): 4
[0031] representing the ring systems (IV.sub.a-d) 5
[0032] wherein
[0033] n is an integer such that 0.ltoreq.n.ltoreq.3,
[0034] W represents an oxygen, sulphur or nitrogen atom, or a group
[C(H).sub.q].sub.p (wherein q is 0, 1 or 2, and p is 1 or 2) or
NR.sub.0 wherein R.sub.0 is as defined hereinbefore,
[0035] the symbol .... is as defined hereinbefore,
[0036] wherein R' substitutes the ring 6
[0037] and R substitutes one or other of the two other rings,
[0038] or a biphenyl group wherein R substitutes one of the benzene
rings and R' substitutes the other, or R and R' substitute the same
benzene ring,
[0039] it being understood that the ring systems of formulae (II),
(III) and (IV) and the biphenyl group may be unsubstituted or
substituted (in addition to the substituents R and R') by from 1 to
6 radicals, which may be the same or different, selected from
R.sub.a, OR.sub.a, COR.sub.a, COOR.sub.a, OCOR.sub.a,
OSO.sub.2CF.sub.3 and halogen atoms,
[0040] wherein R.sub.a represents a hydrogen atom, an unsubstituted
or substituted linear or branched (C.sub.1-C.sub.6)alkyl group, an
unsubstituted or substituted linear or branched
(C.sub.2-C.sub.6)alkenyl group, an unsubstituted or substituted
linear or branched (C.sub.2-C.sub.6)alkynyl group, a linear or
branched (C.sub.1-C.sub.6)polyhaloalkyl group, an unsubstituted or
substituted (C.sub.3-C.sub.8)cycloalkyl group, an unsubstituted or
substituted (C.sub.3-C.sub.8)cycloalkyl-(C.sub.1-C.sub.6)alkyl
group in which the alkyl group is linear or branched, an
unsubstituted or substituted (C.sub.3-C.sub.8)cycloalkenyl group,
an unsubstituted or substituted
(C.sub.3-C.sub.8)cycloalkenyl-(C.sub.1-C.sub.6)alkyl group in which
the alkyl group is linear or branched, an aryl group, an
aryl-(C.sub.1-C.sub.6)alkyl group in which the alkyl moiety is
linear or branched, an aryl-(C.sub.1-C.sub.6)alkenyl group in which
the alkenyl moiety is linear or branched, a heteroaryl group, a
heteroaryl-(C.sub.1-C.sub.6)alkyl group in which the alkyl moiety
is linear or branched, a heteroaryl-(C.sub.1-C.sub.6)alkenyl group
in which the alkenyl moiety is linear or branched, an unsubstituted
or substituted linear or branched (C.sub.1-C.sub.6)heterocycloalkyl
group, an unsubstituted or substituted heterocycloalkenyl group, a
substituted or unsubstituted
heterocycloalkyl-(C.sub.1-C.sub.6)alkyl group in which the alkyl
moiety is linear or branched, or a substituted or unsubstituted
heterocycloalkenyl-(C.sub.1-C.sub.6)alkyl group in which the alkyl
moiety is linear or branched,
[0041] .diamond-solid. R represents:
[0042] a group of formula (V): 7
[0043] wherein
[0044] Q represents a sulphur or oxygen atom,
[0045] R.sup.1 represents a group NR'.sub.aR".sub.a or
OR.sup.1.sub.a (wherein R'.sub.a and R".sub.a, which may be the
same or different, may take any of the values of R.sub.a and may
also form, together with the nitrogen atom carrying them, a 5- to
10-membered cyclic group which may contain, in addition to the
nitrogen atom by which it is linked, from one to three hetero atoms
selected from oxygen, sulphur and nitrogen,
[0046] and R.sup.1.sub.a may take any of the values of R.sub.a
except for the hydrogen atom),
[0047] a group of formula (VI): 8
[0048] wherein
[0049] R.sup.2 represents a group R.sub.a as defined
hereinbefore,
[0050] R.sup.3 represents a group COR'.sub.a, CSR'.sub.a,
CONR'.sub.aR".sub.a, CSNR'.sub.aR".sub.a, COOR'.sub.a, CSOR'.sub.a
or S(O).sub.vR'.sub.a (wherein R'.sub.a and R".sub.a, which may be
the same or different, are as defined hereinbefore and may also
form, together with the nitrogen atom carrying them, a cyclic group
as defined hereinbefore, and v is 1 or 2),
[0051] a group of formula (VII): 9
[0052] wherein v is as defined hereinbefore and R.sup.4 represents
a group NR'.sub.aR".sub.a, NR.sub.aCOR'.sub.a, NR.sub.aCSR'.sub.a,
NR.sub.aCONR'.sub.aR".sub.a, NR.sub.aCSNR'.sub.aR".sub.a or
NR.sub.aCOOR'.sub.a, wherein R.sub.a, R'.sub.a and R".sub.a are as
defined hereinbefore,
[0053] or, when A represents a ring system of formula (II) or (III)
or a biphenyl group, forms, together with two adjacent carbon atoms
of the ring structure A carrying it,
[0054] a ring of formula (VIII): 10
[0055] the ring formed containing from 5 to 7 atoms and it being
possible for the said ring to contain from 1 to 3 hetero atoms
selected from nitrogen, sulphur and oxygen, and one or more
unsaturations, and being optionally substituted by one or more
radicals, which may be the same or different, selected from
R.sub.a, OR.sub.a, COR.sub.a, COOR.sub.a, OCOR.sub.a,
NR'.sub.aR".sub.a, NR.sub.aCOR'.sub.a, CONR'.sub.aR".sub.a, cyano,
oxo, SR.sub.a, S(O)R.sub.a, SO.sub.2R.sub.a, CSR.sub.a,
NR.sub.aCSR'.sub.a, CSNR'.sub.aR".sub.a,
NR.sub.aCONR'.sub.aR".sub.a, NR.sub.aCSNR'.sub.aR".sub.a and
halogen atoms,
[0056] wherein R.sub.a, R'.sub.a and R".sub.a, which may be the
same or different, are as defined hereinbefore and R'.sub.a and
R".sub.a may also form, together with the nitrogen atom carrying
them, a cyclic group as defined hereinbefore,
[0057] .diamond-solid. and R' represents a group of formula
(IX):
-G-R.sup.5 (IX)
[0058] wherein
[0059] G represents an alkylene chain --(CH.sub.2).sub.t-- (wherein
t is an integer such that 0.ltoreq.t.ltoreq.4 when A represents a
tricyclic structure and such that 1.ltoreq.t.ltoreq.4 when A
represents a bicyclic structure), optionally substituted by one or
more radicals, which may be the same or different, selected from
R.sub.a, OR.sub.a, COOR.sub.a, COR.sub.a (in which R.sub.a is as
defined hereinbefore) or halogen atoms,
[0060] and R.sup.5 represents a group 11
[0061] wherein Q, R.sub.a, R'.sub.a and R".sub.a (which may be the
same or different) are as defined hereinbefore, it being possible
for R'.sub.a and R".sub.a to form, together with the nitrogen atom
carrying them, a cyclic group as defined hereinbefore,
[0062] it being understood that:
[0063] "heterocycloalkyl" is taken to mean any saturated mono- or
poly-cyclic group containing from 5 to 10 atoms containing from 1
to 3 hetero atoms selected from nitrogen, oxygen and sulphur,
[0064] "heterocycloalkenyl" is taken to mean any non-aromatic mono-
or poly-cyclic group containing one or more unsaturations,
containing from 5 to 10 atoms and which may contain from 1 to 3
hetero atoms selected from nitrogen, oxygen and sulphur,
[0065] the term "substituted" used in respect of the expressions
"alkyl", "alkenyl" and "alkynyl" indicates that the groups in
question are substituted by one or more radicals, which may be the
same or different, selected from hydroxy, linear or branched
(C.sub.1-C.sub.6)alkoxy, linear or branched (C.sub.1-C.sub.6)alkyl,
linear or branched (C.sub.1-C.sub.6)polyhaloalkyl, amino and
halogen atoms,
[0066] the term "substituted" used in respect of the expressions
"cycloalkyl", "cycloalkylalkyl", "cycloalkenyl",
"cycloalkenylalkyl". "heterocycloalkyl", "heterocycloalkenyl",
"hetero-cycloalkylalkyl" and "heterocycloalkenylalkyl" indicates
that the cyclic moiety of the groups in question is substituted by
one or more radicals, which may be the same or different, selected
from hydroxy, linear or branched (C.sub.1-C.sub.6)alkoxy, linear or
branched (C.sub.1-C.sub.6)alkyl, linear or branched
(C.sub.1-C.sub.6)polyhaloalkyl, amino and halogen atoms,
[0067] "aryl" is taken to mean any aromatic, mono- or poly-cyclic
group containing from 6 to 22 carbon atoms, and also the biphenyl
group,
[0068] "heteroaryl" is taken to mean any aromatic mono- or
poly-cyclic group containing from 5 to 10 atoms containing from 1
to 3 hetero atoms selected from nitrogen, oxygen and sulphur,
[0069] it being possible for the "aryl" and "heteroaryl" groups to
be substituted by one or more radicals, which may be the same or
different, selected from hydroxy, linear or branched
(C.sub.1-C.sub.6)alkoxy, linear or branched (C.sub.1-C.sub.6)alkyl,
linear or branched (C.sub.1-C.sub.6)polyhaloalkyl, cyano, carboxy,
nitro, amino and halogen atoms,
[0070] it being understood that:
[0071] when A represents an indole nucleus, there cannot be any
substituents in the 2-position,
[0072] when A represents an indole nucleus and R represents a group
--NHCOR'.sub.a, --NHCOOR'.sub.a or NHCONR'.sub.aR".sub.a, then
G-R.sup.5 cannot represent a group --CH.sub.2).sub.2--NHCOR.sub.b
wherein R.sub.b represents a (C.sub.1-C.sub.4)alkyl or CF.sub.3
group,
[0073] when A represents a benzofuran or benzothiophene nucleus,
there cannot be any COPh groups (wherein Ph is substituted or
unsubstituted) in the 2-position,
[0074] when A represents a benzofuran or benzothiophene nucleus, R
cannot represent a group --NR.sub.aCOR.sub.c, --NHSO.sub.2R.sub.c,
--NHCOCH.sub.2R.sub.c, or NHCONHR.sub.c wherein R.sub.c represents
a heterocyclic or aryl group,
[0075] when A represents a tetrahydronaphthalene group, R.sup.5
cannot represent a group CONR'.sub.aR".sub.a,
[0076] when A represents a hydrocarbon ring system and R.sup.5
represents a group NHCOR'.sub.a, then R cannot represent a group
COOR'.sub.a,
[0077] the compound of formula (I) cannot represent:
[0078]
N-{8-[(acetylamino)methyl]-2-naphthyl}-2-methylpropanamide,
[0079]
N-(2-{5-[(4-ethoxyanilino)sulphonyl]-1H-indol-3-yl}ethyl)acetamide,
[0080] 8-[(acetylamino)methyl]-N-isopropyl-2-naphthamide,
[0081] their enantiomers and diastereoisomers, and addition salts
thereof with a pharmaceutically acceptable acid or base.
[0082] Among the pharmaceutically acceptable acids there may
mentioned, without implying any limitation, hydrochloric acid,
hydrobromic acid, sulphuric acid, phosphonic acid, acetic acid,
trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid,
succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic
acid, citric acid, ascorbic acid, methanesulphonic acid, camphoric
acid, oxalic acid etc.
[0083] Among the pharmaceutically acceptable bases there may
mentioned, without implying any limitation, sodium hydroxide,
potassium hydroxide, triethylamine, tert-butylamine etc.
[0084] Preferred compounds of the invention are those wherein A
represents a ring system of formula (II'): 12
[0085] wherein B, X and the symbol .... are as defined
hereinbefore, or (III'): 13
[0086] wherein B', T', X' and the symbol .... are as defined
hereinbefore.
[0087] The invention advantageously relates to compounds wherein A
(unsubstituted or substituted by a single substituent (in addition
to R and R') preferably in the 2-position (formula II') or in the
3-position (formula III'), represents a cyclic system of formula
(II'): 14
[0088] wherein B, X and the symbol .... are as defined
hereinbefore, such as, for example, (dihydro)benzothiophene,
(dihydro)benzofuran, indole, indoline, indan, indene, azaindole,
thienopyridine or furopyridine, or of formula (III'): 15
[0089] wherein B', T', X' and the symbol .... are as defined
hereinbefore, such as, for example, naphthalene,
tetrahydronaphthalene, (thio)chroman, (dihydro)benzodioxin,
(dihydro)benzoxathiin, (dihydro)benzochromene.
[0090] Even more advantageously, the invention relates to compounds
wherein A of formula (II') or (III') is substituted by R in the
5-position (formula II') or 7-position (formula III') and by R' in
the 3-position (formula II') or 1- or 2-position (formula
III').
[0091] Preferred substituents R of the invention are those
represented by a group of formula (V), (VI) or (VII).
[0092] More advantageously, preferred substituents R of the
invention are those represented by a group of formula (V) wherein Q
represents an oxygen atom and R' represents a group
NR'.sub.aR".sub.a (wherein R'.sub.a and R".sub.a are as defined
hereinbefore) or OR.sup.1.sub.a (wherein R.sup.1.sub.a is as
defined hereinbefore),
[0093] a group of formula (VI) wherein R.sup.3 represents a group
COR'.sub.a or COOR'.sub.a (wherein R'.sub.a is as defined
hereinbefore),
[0094] or a group of formula (VII) wherein v is 2 and R.sup.4
represents a group NR'.sub.aR".sub.a as defined hereinbefore.
[0095] Even more advantageously, preferred substituents R of the
invention are those represented by a group CONR'.sub.aR".sub.a or
SO.sub.2NR'.sub.aR".sub.a wherein R'.sub.a and R".sub.a, which may
be the same or different, represent a hydrogen atom or an alkyl,
polyhaloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
cycloalkylalkyl, cycloalkenylalkyl, aryl, arylalkyl, heteroaryl or
heteroarylalkyl group, such as, for example, methyl, ethyl, propyl,
isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,
isopentyl, hexyl, trifluoromethyl, vinyl, allyl, propargyl, phenyl,
naphthyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cyclohexenyl, methylcyclopropyl, ethylcyclopropyl,
furyl, thienyl, pyridyl, furylmethyl, pyridylmethyl, or form,
together with the nitrogen atom carrying them, a piperazine,
piperidine, morpholine or thiomorpholine group, or by a group
NCOR'.sub.a, NCOOR'.sub.a or COOR'.sub.a wherein R'.sub.a
represents a hydrogen atom, an alkyl, polyhaloalkyl, alkenyl,
alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl
group, such as, for example, methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl,
trifluoromethyl, vinyl, allyl, propargyl, phenyl, naphthyl, benzyl,
phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclohexenyl, methylcyclopropyl, ethylcyclopropyl, furyl, thienyl,
pyridyl, furylmethyl, pyridylmethyl, and R.sup.1.sub.a represents
an alkyl, polyhaloalkyl, alkenyl, alkynyl, cycloalkyl, aryl,
arylalkyl, heteroaryl or heteroarylalkyl group, such as, for
example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl,
sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, trifluoromethyl,
vinyl, allyl, propargyl, phenyl, naphthyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl,
methylcyclopropyl, ethylcyclopropyl, furyl, thienyl, pyridyl,
furylmethyl, pyridylmethyl.
[0096] Preferred substituents R' of the invention are those wherein
G represents an unsubstituted or substituted alkylene chain
--(CH.sub.2).sub.t--, wherein t is 2 or 3, and R.sup.5 represents a
group 16
[0097] wherein R.sub.a, R'.sub.a, R".sub.a and Q are as defined
hereinbefore.
[0098] Even more advantageously, preferred substituents R' of the
invention are those wherein G represents a group
--(CH.sub.2).sub.t--, wherein t is 2 or 3, and R.sup.5 represents a
group 17
[0099] wherein R'.sub.a represents an alkyl, polyhaloalkyl,
alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloakylalkyl,
cycloalkenylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl
group, such as, for example, methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl,
trifluoromethyl, vinyl, allyl, propargyl, phenyl, naphthyl, benzyl,
phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclohexenyl, methylcyclopropyl, ethylcyclopropyl, furyl, thienyl,
pyridyl, furylmethyl, pyridylmethyl, or G represents a group
--(CH.sub.2).sub.3-- and R.sup.5 represents a group 18
[0100] wherein R.sub.a represents an alkyl, polyhaloalkyl, alkenyl,
alkynyl, cycloalkyl, cycloalkenyl, cycloakylalkyl,
cycloalkenylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl
group, such as, for example, methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl,
trifluoromethyl, vinyl, allyl, propargyl, phenyl, naphthyl, benzyl,
phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclohexenyl, methylcyclopropyl, ethylcyclopropyl, furyl, thienyl,
pyridyl, furylmethyl, pyridylmethyl.
[0101] More especially, preferred compounds of the invention are
those wherein A represents a ring system of formula (II') or (III')
and R represents a group of formula (V), (VI) or (VII).
[0102] More advantageously, the invention relates to compounds
wherein:
[0103] A represents a group of formula (II') or (III') substituted
in the 5-position (formula II') or 7-position (formula III') by R
and in the 3-position (formula II') or 1- or 2-position (formula
III') by R',
[0104] and R represents a group CONR'.sub.aR".sub.a,
SO.sub.2NR'.sub.aR".sub.a, COOR.sup.1.sub.a, NHCOR'.sub.a or
NHCOOR'.sub.a (wherein R'.sub.a, R".sub.a and R.sup.1.sub.a are as
defined hereinbefore).
[0105] Even more advantageously, preferred compounds of the
invention are those wherein A represents a ring system of formula
(II') or (III') optionally substituted (in addition to R and R') by
a substituent in the 2-position (formula II') or 3-position
(formula III'),
[0106] substituted in the 5-position (formula II') or 7-position
(formula III') by R and in the 3-position (formula II') or I-- or
2-position (formula III') by R',
[0107] R represents a group CONR'.sub.aR".sub.a,
SO.sub.2NR'.sub.aR".sub.a- , COOR.sup.1.sub.a, NHCOR'.sub.a or
NHCOOR'.sub.a (wherein R'.sub.a, R".sub.a and R.sup.1.sub.a are as
defined hereinbefore),
[0108] and R' is such that G represents an unsubstituted or
substituted alkylene chain --(CH.sub.2).sub.t--, wherein t is 2 or
3, and R.sup.5 represents a group 19
[0109] wherein R.sub.a, R'.sub.a, R".sub.a and Q are as defined
hereinbefore.
[0110] Even more especially, the invention relates to
(dihydro)benzothiophenes, (dihydro)benzofurans, indoles, indolines,
indenes, indans, azaindoles, thieno- or furopyridines optionally
substituted in the 2-position, and to dihydronaphthalenes,
tetrahydronaphthalenes, naphthalenes or chromans optionally
substituted in the 3-position,
[0111] substituted in the 5-position (or 7-position, respectively)
by a group CONR'.sub.aR".sub.a, SO.sub.2NR'.sub.aR".sub.a,
COOR.sup.1.sub.a, NHCOR'.sub.a or NHCOOR'.sub.a wherein R'.sub.a
and R".sub.a, which may be the same or different, represent a
hydrogen atom, an alkyl, polyhaloalkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, cycloakylalkyl, cycloalkenylalkyl, aryl,
arylalkyl, heteroaryl or heteroarylalkyl group, such as, for
example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl,
sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, trifluoromethyl,
vinyl, allyl, propargyl, phenyl, naphthyl, benzyl, phenethyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl,
methylcyclopropyl, ethylcyclopropyl, furyl, thienyl, pyridyl,
furylmethyl, pyridylmethyl, or R'.sub.a and R".sub.a form, together
with the nitrogen atom carrying them, a piperazine, piperidine,
morpholine or thiomorpholine group, and R.sup.1.sub.a represents an
alkyl, polyhaloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
cycloakylalkyl, cycloalkenylalkyl, aryl, arylalkyl, heteroaryl or
heteroarylalkyl group, such as, for example, methyl, ethyl, propyl,
isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,
isopentyl, hexyl, trifluoromethyl, vinyl, allyl, propargyl, phenyl,
naphthyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cyclohexenyl, methylcyclopropyl, ethylcyclopropyl,
furyl, thienyl, pyridyl, furylmethyl, pyridylmethyl,
[0112] and substituted in the 3-position (or 1- or 2-position,
respectively) by a group --(CH.sub.2).sub.t--NHCOR'.sub.a wherein t
is 2 or 3 and R'.sub.a represents an alkyl, polyhaloalkyl, alkenyl,
alkynyl, cycloalkyl, cycloalkenyl, cycloakylalkyl,
cycloalkenylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl
group, such as, for example, methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl,
trifluoromethyl, vinyl, allyl, propargyl, phenyl, naphthyl, benzyl,
phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclohexenyl, methylcyclopropyl, ethylcyclopropyl, furyl, thienyl,
pyridyl, furylmethyl, pyridylmethyl.
[0113] Even more advantageously, preferred compounds of the
invention are:
[0114] naphthalenes, dihydronaphthalenes or tetrahydronaphthalenes
optionally substituted in the 3-postion, substituted in the
7-position by a group NHCOR.sub.a, NHCOOR.sub.a, CONHR.sub.a or
COOR.sup.1.sub.a (wherein R.sub.a and R.sup.1.sub.a are as defined
hereinbefore) and substituted in the 1-position by a group
--(CH.sub.2).sub.t--NHCOR'.sub.a wherein t is 2 or 3 and R'.sub.a
is as defined hereinbefore,
[0115] or benzofurans or benzothiophenes optionally substituted in
the 2-position, substituted in the 5-position by a group
NHCOR.sub.a, NHCOOR.sub.a, CONHR.sub.a or COOR.sup.1.sub.a (wherein
R.sub.a and R.sup.1.sub.a are as defined hereinbefore) and
substituted in the 3-position by a group
--(CH.sub.2).sub.t--NHCOR'.sub.a wherein t is 2 or 3 and R'.sub.a
is as defined hereinbefore.
[0116] The invention relates very particularly to the compounds of
formula (I) that are
[0117]
N-{2-[6-(acetylamino)-2,3-dihydro-1H-1-indenyl]ethyl}acetamide,
[0118] methyl
3-[2-(2-furoylamino)ethyl]-1-benzofuran-5-carboxylate,
[0119] methyl
3-{2-[(cyclopentylcarbonyl)amino]ethyl}-1-benzofuran-5-carbo-
xylate,
[0120] methyl
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-1-benzofuran-5-carbo-
xylate,
[0121] methyl
3-[2-(3-butenoylamino)ethyl]-1-benzofuran-5-carboxylate,
[0122]
N,N-diphenyl-3-[3-(acetylamino)propyl]benzo[b]furan-5-carboxamide,
[0123] 3-[2-(acetylamino)ethyl]-1-benzofuran-5-carboxamide,
[0124]
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-1-benzofuran-5-carboxamide,
[0125] 3-[2-(2-furoylamino)ethyl]-1-benzofuran-5-carboxamide,
[0126]
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-N-methyl-1-benzofuran-5-car-
boxamide,
[0127]
3-[2-(acetylamino)ethyl]-N-methyl-1-benzofuran-5-carboxamide,
[0128]
3-{2-[(cyclopentylcarbonyl)amino]ethyl}-N-methyl-1-benzofuran-5-car-
boxamide,
[0129]
3-[2-(benzoylamino)ethyl]-N-methyl-1-benzofuran-5-carboxamide,
[0130]
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-N-methyl-1-benzofuran-5-car-
boxamide,
[0131]
3-[2-(benzoylamino)ethyl]-N-methyl-1-benzofuran-5-carboxamide,
[0132]
3-[2-(acetylamino)ethyl]-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carbo-
xamide,
[0133]
N-isopropyl-N-(2-propynyl)-3-[(acetylamino)methyl]-2-benzylbenzo[b]-
thiophene-5-carboxamide,
[0134]
N-{3-[2-(acetylamino)ethyl]-1-benzofuran-5-yl}-2,2,2-trifluoroaceta-
mide,
[0135]
N-{2-[5-(acetylamino)-1-benzofuran-3-yl]ethyl}cyclopropanecarboxami-
de,
[0136]
N-{2-[5-(acetylamino)-1-benzothiophen-3-yl]ethyl}benzamide,
[0137]
N-{8-[2-([2-phenylacetyl]amino)ethyl]-2-naphthyl}butanamide,
[0138]
N-(8-{2-[(2-bromoacetyl)amino]ethyl}-2-naphthyl)-1-cyclohexanecarbo-
xamide,
[0139]
N-{8-[2-(heptanoylamino)ethyl]-2,6-dinaphthyl}-2-butenamide,
[0140] N-{8-[2-(acetylamino)ethyl]-2-naphthyl}acetamide,
[0141]
N-ethyl-8-{2-[(2-phenylacetyl)amino]ethyl}-2-naphthamide,
[0142]
N,N-diethyl-8-{2-[2-[(cyclopropylmethyl)amino]-2-oxoethyl}-2-naphth-
amide,
[0143]
N-phenyl-8-(2-{methyl[(propylamino)carbonyl]amino}ethyl)-2-naphtham-
ide,
[0144]
N-benzyl-1-{2-[(2,2,2-trifluoroacetyl)amino]ethyl}-2-naphthamide,
[0145]
N-(2-{7-[(methylamino)carbonyl]-1-naphthyl}ethyl)-2-furamide,
[0146] N-{2-[7-(aminosulphonyl)-1-naphthyl]ethyl}acetamide,
[0147]
N-(2-{7-[(methylamino)sulphonyl]-1-naphthyl}ethyl)acetamide,
[0148]
N-(2-{7-[(methylamino)sulphonyl]-1-naphthyl}ethyl)-2-furamide,
[0149]
N-(2-{7-[(ethylamino)sulphonyl]-1-naphthyl}ethyl)benzamide,
[0150]
N-(2-{7-[(methylamino)sulphonyl]-1-naphthyl}ethyl)cyclopropanecarbo-
xamide,
[0151]
N-(3-{5-[(methylamino)sulphonyl]-1-benzofuran-3-yl}propyl)acetamide-
,
[0152]
N-(2-{5-[(propylamino)sulphonyl]-1-benzofuran-3-yl}ethyl)acetamide,
[0153]
N-(2-{5-[(cyclopropylamino)sulphonyl]-1-benzofuran-3-yl}ethyl)benza-
mide,
[0154]
N-(2-{5-[(methylamino)sulphonyl]-1-benzofuran-3-yl}ethyl)-2-furamid-
e,
[0155] N-(2-{5-[(methyl
amino)sulphonyl]-1-benzofuran-3-yl}ethyl)cycloprop-
anecarboxamide,
[0156]
N-(2-{2-benzyl-5-[(methylamino)sulphonyl]-1-benzothiophen-3-yl}ethy-
l)acetamide,
[0157]
N-(2-{5-[(isopropylamino)sulphonyl]-1-benzothiophen-3-yl}ethyl)cycl-
opropanecarboxamide,
[0158]
N-(2-{5-[(methylamino)sulphonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}ethy-
l)acetamide,
[0159] N-(2-{5-[(methylamino)sulphonyl]-1H-pyrrolo[2,
3-b]pyridin-3-yl}ethyl)cyclopropanecarboxamide,
[0160]
N-(2-{5-[(methylamino)sulphonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}ethy-
l)benzamide,
[0161] N-(2-{5-[(methylamino)sulphonyl]-1H-pyrrolo[2,
3-b]pyridin-3-yl}ethyl)-2-furamide,
[0162] methyl
N-{3-[2-(acetylamino)ethyl]benzo[b]furan-5-yl}carbamate,
[0163] methyl
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-1-benzofuran-5-yl-ca-
rbamate,
[0164] tert-butyl
3-[2-(acetylamino)ethyl]-1-benzofuran-5-yl-carbamate,
[0165] tert-butyl
3-[2-(acetylamino)ethyl]-1-benzofuran-5-yl-(methyl)carba- mate,
[0166] methyl
3-[2-(benzoylamino)ethyl]-1-benzofuran-5-yl-carbamate,
[0167] methyl
3-[2-(isobutyrylamino)ethyl]-1-benzofuran-5-yl-carbamate,
[0168] methyl
5-[(acetylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl-car-
bamate,
[0169] methyl
3-[(acetylamino)methyl]-3,4-dihydro-2H-chromen-6-yl-carbamat-
e,
[0170] ethyl
3-[2-(acetylamino)ethyl]-2,3-dihydro-1H-inden-5-yl-carbamate,
[0171] methyl
3-[2-(acetylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl-carba-
mate,
[0172] methyl 3-[2-(2-furoylamino)ethyl]-1H-pyrrolo[2,
3-b]pyridin-5-yl-carbamate,
[0173] methyl 3-[2-(benzoylamino)ethyl]-1H-pyrrolo[2,
3-b]pyridin-5-yl-carbamate,
[0174] methyl 3-{2-[(cyclopropylcarbonyl)amino]ethyl}-1-pyrrolo[2,
3-b]pyridin-5-yl-carbamate,
[0175] ethyl
N-(8-{2-[(2-bromoacetyl)amino]ethyl}-2-naphthyl)carbamate,
[0176] methyl
N-{8-[2-(acetylamino)ethyl]-6-phenyl-2-naphthyl}carbamate,
[0177] hexyl
N-{8-[2-(acetylamino)ethyl]-5,6,7,8-tetrahydro-2-naphthyl}car-
bamate,
[0178] methyl 8-[2-(acetylamino)ethyl]-2-naphthyl-carbamate,
[0179] methyl
3-[2-(2-furoylamino)ethyl]-1-benzofuran-5-yl-carbamate,
[0180] methyl
3-{2-[(cyclopentylcarbonyl)amino]ethyl}-1-benzofuran-5-yl-ca-
rbamate,
[0181] methyl
3-[2-(benzoylamino)ethyl]-1-benzofuran-5-carboxylate,
[0182] methyl
3-[2-(isobutylamino)ethyl]-11-benzofuran-5-carboxylate,
[0183] 3-[2-(benzoylamino)ethyl]-1-benzofuran-5-carboxamide.
[0184] The enantiomers and diastereoisomers, as well as the
addition salts with a pharmaceutically acceptable acid or base, of
the preferred compounds of the invention form an integral part of
the invention.
[0185] The invention relates also to a process for the preparation
of compounds of formula (I), which process is characterised in that
there is used as starting material the compound of formula (X)
20
[0186] wherein A and R' are as defined hereinbefore, which is
subjected to demethylation using conventional agents such as HBr,
AlCl.sub.3, AlBr.sub.3, BBr.sub.3 or Lewis acid/nucleophile binary
systems such as AlCl.sub.3/PhCH.sub.2SH, or BBr.sub.3/Me.sub.2S,
for example, to obtain the compound of formula (XI):
HO-A-R' (XI)
[0187] wherein A and R' are as defined hereinbefore,
[0188] .diamond-solid. which is converted, by means of the action
of reagents such as POCl.sub.3, PCl.sub.5, Ph.sub.3PBr.sub.2,
PhPCl.sub.4, HBr or HI, into the corresponding halogenated compound
of formula (XII):
Hal-A-R' (XII)
[0189] wherein A and R' are as defined hereinbefore and Hal
represents a halogen atom (which compounds of formula (XII) can be
obtained by exchange reactions such as, for example, the treatment
of a chlorinated compound with KI in dimethylformamide to yield the
corresponding fluorinated compound or the treatment of a brominated
compound with KI in the presence of copper salts to yield the
corresponding iodinated compound), which is treated with carbon
monoxide and Bu.sub.3SnH, the reaction being catalysed with
palladium (0), to yield the corresponding aldehyde of formula
(XIII): 21
[0190] wherein A and R' are as defined hereinbefore,
[0191] which compound of formula (XIII) may alternatively be
obtained by customary lithiation methods starting from the
halogenated compound of formula (XII), or via the corresponding
vinyl compound (obtained starting from the compound of formula
(XII) by the action of vinyltributyltin and tetrakis palladium)
subjected to ozonolysis, or furthermore by direct formylation of
the nucleus A, for example according to a Vilsmeier reaction,
[0192] which compound of formula (XIII) is subjected to an
oxidising agent to obtain the compound of formula (XIV):
HOOC-A-R' (XIV)
[0193] wherein A and R' are as defined hereinbefore, which is:
[0194] either subjected, in the presence of an acid catalyst, to
the action of an alcohol of formula R.sup.1.sub.aOH, wherein
R.sup.1.sub.a is as defined hereinbefore, to yield the compound of
formula (I/a), a particular case of the compounds of formula (I):
22
[0195] wherein A, R.sup.1.sub.a and R' are as defined
hereinbefore,
[0196] which may be subjected to a thionating agent, such as
Lawesson's reagent, for example, to yield the compound of formula
(I/b), a particular case of the compounds of formula (I): 23
[0197] wherein A, R.sup.1.sub.a and R' are as defined
hereinbefore,
[0198] or converted, after the action of thionyl chloride and an
azide, and then of an acid, into the compound of formula (XV):
H.sub.2N-A-R' (XV)
[0199] wherein A and R' are as defined hereinbefore, with which
there is condensed
[0200] either an acyl chloride ClCOR.sub.a or the corresponding
anhydride (mixed or symmetrical), wherein R.sub.a is as defined
hereinbefore, to yield the compound of formula (I/c), a particular
case of the compounds of formula (I): 24
[0201] wherein R.sub.a, A and R' are as defined hereinbefore,
[0202] which may be subjected to the action of a compound of
formula (XVI):
R.sup.1.sub.a-J (XVI)
[0203] wherein R.sup.1.sub.a is as defined hereinbefore and J
represents a leaving group such as a halogen atom or a tosyl
group,
[0204] to obtain the compound of formula (I/d), a particular case
of the compounds of formula (I): 25
[0205] wherein R.sub.a, R.sup.1.sub.a, A and R' are as defined
hereinbefore,
[0206] which compounds of formulae (I/c) and (I/d) constitute the
compound of formula (I/e), a particular case of the compounds of
formula (I): 26
[0207] wherein R.sub.a, R'.sub.a, A and R' are as defined
hereinbefore,
[0208] which compound of formula (I/e) may be subjected to a
thionating agent, such as Lawesson's reagent, for example, to
obtain the compound of formula (I/f), a particular case of the
compounds of formula (I) 27
[0209] wherein R.sub.a, R'.sub.a, A and R' are as defined
hereinbefore,
[0210] or a compound of formula (XVII):
Q=C.dbd.N--R'.sub.a (XVII)
[0211] wherein Q and R'.sub.a are as defined hereinbefore,
[0212] to yield the compound of formula (I/g), a particular case of
the compounds of formula (I): 28
[0213] wherein R'.sub.a Q, A and R' are as defined
hereinbefore,
[0214] which may be subjected to the action of a compound of
formula (XVI) to obtain the compound of formula (I/h), a particular
case of the compounds of formula (I): 29
[0215] wherein Q, R.sup.1.sub.a, A and R' are as defined
hereinbefore and R.sup.2.sub.a and R'.sup.2.sub.a, which may be the
same or different, may take any of the values of R.sub.a except for
the hydrogen atom and cannot form a cyclic structure together with
the nitrogen atom carrying them,
[0216] or a compound of formula (XVIII): 30
[0217] wherein R'.sub.a is as defined hereinbefore, or its
corresponding anhydride (R'.sub.aOCO).sub.2O,
[0218] to obtain the compound of formula (I/i), a particular case
of the compounds of formula (I): 31
[0219] wherein R'.sub.a, A et R' are as defined hereinbefore,
[0220] which may be subjected to the action of a compound of
formula (XVI) and/or the action of a thionating agent to yield the
compound of formula (I/j), a particular case of the compounds of
formula (I): 32
[0221] wherein R.sub.a, R'.sub.a, Q, A and R' are as defined
hereinbefore,
[0222] or a compound of formula (XIX):
R.sub.aSO.sub.2Cl (XIX)
[0223] wherein R.sub.a is as defined hereinbefore,
[0224] optionally followed by the action of a compound of formula
(XVI) to yield the compound of formula (I/k), a particular case of
the compounds of formula (I): 33
[0225] wherein R.sub.a, A and R' are as defined hereinbefore,
[0226] .diamond-solid. or which compound of formula (XI) is
converted, by means of the action of benzylthiol and
trifluoromethanesulphonic acid, into the corresponding benzylthio
compound of formula (XX):
Ph--CH.sub.2--S-A-R' (XX)
[0227] wherein A and R' are as defined hereinbefore,
[0228] which is placed in the presence of iodosobenzene and
hydrochloric acid to yield the compound of formula (XXI):
ClSO.sub.2-A-R' (XXI)
[0229] wherein A and R' are as defined hereinbefore,
[0230] with which there is condensed an amine R'.sub.aR".sub.aNH
(wherein R'.sub.a and R".sub.a are as defined hereinbefore),
[0231] to obtain the compound of formula (I/l), a particular case
of the compounds of formula (I):
R'.sub.aR".sub.aNSO.sub.2-A-R' (I/l)
[0232] wherein R'.sub.a, R".sub.a, A and R' are as defined
hereinbefore,
[0233] it being possible for the compound of formula (I/la), a
particular case of the compounds of formula (I/l):
H.sub.2NSO.sub.2-A-R' (I/la)
[0234] wherein A and R' are as defined hereinbefore, to be
subjected to the action
[0235] of an acyl chloride ClCOR'.sub.a, optionally followed by the
action of a compound of formula (XVI) and/or Lawesson's
reagent,
[0236] to yield the compound of formula (I/m), a particular case of
the compounds of formula (I): 34
[0237] wherein R.sub.a, R'.sub.a, Q, A and R' are as defined
hereinbefore,
[0238] of a compound of formula (XVII), optionally followed by the
action of a compound of formula (XVI) to obtain the compound of
formula (I/n), a particular case of the compounds of formula (I)
35
[0239] wherein R.sub.a, R'.sub.a, R".sub.a, Q, A and R' are as
defined hereinbefore,
[0240] or of a compound of formula (XVIII), optionally followed by
the action of a compound of formula (XVI),
[0241] to yield the compound of formula (I/o), a particular case of
the compounds of formula (I): 36
[0242] wherein R.sub.a, R'.sub.a, A and R' are as defined
hereinbefore,
[0243] which compounds (I/a) to (I/o) can be purified in accordance
with a conventional separation technique, are converted, if
desired, into their addition salts with a pharmaceutically
acceptable acid or base and, optionally, are separated into their
isomers in accordance with a conventional separation technique.
[0244] The starting compounds (X) are either commercially available
or are described in the literature, for example in the Patent
Applications EP0447285, EP0527687, EP0562956, EP0591057, EP0662471,
EP0745586, EP0709371, EP0745583, EP0721938, EP0745584, EP0737670,
EP0737685, or WO9738682.
[0245] Another advantageous process of the invention relating to
preparation of the compounds of formula (I) is characterised in
that there is used as starting material the compound of formula
(XXII): 37
[0246] wherein R and the symbol .... are as defined hereinbefore,
Y" represents a group C(H).sub.q (wherein q is 0, 1 or 2) or a
bond, and X" represents an oxygen, nitrogen or sulphur atom or a
group C(H).sub.q (wherein q is 0, 1 or 2) or NR.sub.0 (wherein
R.sub.0 is as defined hereinbefore), it being understood that when
X" represents a nitrogen atom or a group NR.sub.0 then Y"
represents a bond,
[0247] which is subjected to a Wittig reaction and then to
reduction to yield the compound of formula (XXIII): 38
[0248] wherein R, X", Y" G and the symbol .... are as defined
hereinbefore,
[0249] which may be oxidised to yield the compound of formula
(XXIV): 39
[0250] wherein R.sup.1, X", Y", G and the symbol .... are as
defined hereinbefore,
[0251] which is:
[0252] either hydrolysed in an acid or basic medium and then
subjected, after activation to the acid chloride form or in the
presence of a coupling agent, to the action of an amine
HNR'.sub.aR".sub.a wherein R'.sub.a and R".sub.a are as defined
hereinbefore to yield the compound of formula (I/p), a particular
case of the compounds of formula (I): 40
[0253] wherein R, X", Y", G, R'.sub.a, R".sub.a and the symbol ....
are as defined hereinbefore,
[0254] which may be subjected to a thionating agent such as
Lawesson's reagent to yield the compound of formula (I/q), a
particular case of the compounds of formula (I): 41
[0255] wherein R, X", Y", G, R.sup.40 .sub.a, R".sub.a and the
symbol .... are as defined hereinbefore,
[0256] or hydrolysed in an acid or basic medium and then converted
into the corresponding azide to yield, after having been subjected
to a Curtius rearrangement and hydrolysis, the compound of formula
(XXV): 42
[0257] wherein R, X", Y" and G are as defined hereinbefore,
[0258] which is reacted with:
[0259] an acyl chloride ClCOR'.sub.a or the corresponding anhydride
(mixed or symmetrical) wherein R'.sub.a is as defined hereinbefore,
optionally followed by the action of a compound of formula (XVI)
and/or the action of a thionating agent to yield the compound of
formula (I/r), a particular case of the compounds of formula (I):
43
[0260] wherein R, X", Y", G, R.sub.a, R'.sub.a, Q and the symbol
.... are as defined hereinbefore,
[0261] or with a compound of formula (XVII), optionally followed by
the action of a compound of formula (XVI) to yield the compound of
formula (I/s), a particular case of the compounds of formula (I):
44
[0262] wherein R, X", Y", G, R.sub.a, R'.sub.a, R".sub.a, Q and the
symbol .... are as defined hereinbefore.
[0263] which compounds (I/p) to (I/s) can be purified in accordance
with a conventional separation technique, are converted, if
desired, into their addition salts with a pharmaceutically
acceptable acid or base and, optionally, are separated into their
isomers in accordance with a conventional separation technique.
[0264] The compounds of formula (XXII) are either commercially
available or easily accessible to the person skilled in the
art,
[0265] starting from the compound of formula (XXVI) 45
[0266] wherein R is as defined hereinbefore and X'" represents an
oxygen or sulphur atom or a group NR.sub.0 (wherein R.sub.0 is as
defined hereinbefore),
[0267] (the compound of formula (XXVI) either being commercially
available or being obtained starting from the compound of formula
(XXVI'): 46
[0268] wherein X'" is as defined hereinbefore, by conventional
reactions for substitution of the aromatic nucleus),
[0269] which is subjected to the action of AlCl.sub.3 to yield the
compound of formula (XXVII): 47
[0270] wherein R and X'" are as defined hereinbefore, which is
subjected to bromination to obtain the compound of formula
(XXVIII): 48
[0271] wherein X'" and R are as defined hereinbefore, which is
placed in a basic medium to yield the compound of formula (XXIX), a
particular case of the compounds of formula (XXII): 49
[0272] wherein R and X'" are as defined hereinbefore,
[0273] or starting from the compound of formula (XXX): 50
[0274] wherein R, X", Y" and the symbol .... are as defined
hereinbefore,
[0275] which is cyclised in the presence of polyphosphoric acid to
yield the compound of formula (XXII).
[0276] The invention relates also to a process for the preparation
of compounds of formula (I) wherein R represents a ring of formula
(VIII), which process is characterised in that compounds of
formulae (I/a) to (I/s) are used as starting materials, which are
cyclised according to methods described in the literature, for
example in the Patent Applications EP0708099 or WO9732871.
[0277] The compounds of the invention and pharmaceutical
compositions comprising them are proving to be useful in the
treatment of disorders of the melatoninergic system.
[0278] Pharmacological study of the compounds of the invention has
in fact shown them to be non-toxic, to have strong affinity for
melatonin receptors and to possess important activities in respect
of the central nervous system and, in particular, there have been
found therapeutic properties in relation to sleep disorders,
anxiolytic, antipsychotic and analgesic properties and in relation
to the microcirculation, enabling it to be established that the
products of the invention are useful in the treatment of stress,
sleep disorders, anxiety, seasonal affective disorder,
cardiovascular pathologies, pathologies of the digestive system,
insomnia and fatigue resulting from jet lag, schizophrenia, panic
attacks, melancholia, appetite disorders, obesity, insomnia,
psychotic disorders, epilepsy, diabetes, Parkinson's disease,
senile dementia, various disorders associated with normal or
pathological ageing, migraine, memory loss, Alzheimer's disease,
and also cerebral circulation disorders. In another field of
activity, it appears that, in treatment, the products of the
invention can be used in sexual dysfunction, that they have
ovulation-inhibiting properties and immunomodulating properties and
are able to be used in the treatment of cancers.
[0279] The compounds will preferably be used in the treatment of
seasonal affective disorder, sleep disorders, cardiovascular
pathologies, insomnia and fatigue resulting from jet lag, appetite
disorders and obesity.
[0280] For example, the compounds will be used in the treatment of
seasonal affective disorder and sleep disorders.
[0281] The present invention relates also to pharmaceutical
compositions comprising at least one compound of formula (1), alone
or in combination with one or more pharmaceutically acceptable
excipients.
[0282] Among the pharmaceutical compositions according to the
invention there may be mentioned more especially those that are
suitable for oral, parenteral, nasal, per- or trans-cutaneous,
rectal, perlingual, ocular or respiratory administration and
especially tablets, dragees, sublingual tablets, sachets, paquets,
gelatin capsules, glossettes, lozenges, suppositories, creams,
ointments, dermal gels and drinkable or injectable ampoules.
[0283] The dosage varies according to the sex, age and weight of
the patient, the route of administration, the nature of the
therapeutic indication, or possible associated treatments, and
ranges from 0.01 mg to 1 g per 24 hours in 1 or more
administrations.
[0284] The following Examples illustrate the invention but do not
limit it in any way. The following Preparations yield compounds of
the invention or synthesis intermediates that are useful in
preparation of the compounds of the invention.
[0285] Preparation 1:
N-[2-(7-Hydroxy-1-naphthyl)ethyl]acetamide
[0286] Under an inert atmosphere, 27.5 mmol of boron
tribromide/dimethyl sulphide complex are dissolved in 100 ml of
dichloromethane and stirred for 15 min at ambient temperature. A
solution of 13.7 mmol of N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
in 50 ml of dichloromethane is added and the reaction mixture is
heated at reflux for 30 hours. After cooling, the reaction mixture
is hydrolysed with caution and the dichloromethane is evaporated
off. The mixture is then extracted with ethyl acetate, the combined
organic phases are washed with a 1M aqueous solution of potassium
bicarbonate and then with 1M sodium hydroxide solution. The organic
phase is dried over magnesium sulphate and concentrated to yield
the title compound.
[0287] Preparation 2:
N-[2-(7-Hydroxy-1-naphthyl)ethyl]-2-phenylacetamide
[0288] The procedure is as in Preparation 1, but the
N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide is replaced by
N-[2-(7-methoxy-1-naphthyl)ethyl]-2-phenylacetamide.
[0289] In Preparations 3 to 37, the procedure is as in Preparation
1, but the N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide is replaced
by the appropriate methoxylated starting substrate.
[0290] Preparation 3:
N-[2-(7-Hydroxy-1-naphthyl)ethyl]-2-bromoacetamide
[0291] Preparation 4:
N-[2-(8-Hexyl-7-hydroxy-1-naphthyl)ethyl]-2-phenylac- etamide
[0292] Preparation 5:
N-Cyclopropylmethyl-2-(7-hydroxy-1-naphthyl)acetamid- e
[0293] Preparation 6:
N-Cyclohexyl-4-(7-hydroxy-1-naphthyl)butanamide
[0294] Preparation 7:
N-[2-(7-Hydroxy-1-naphthyl)ethyl]-N-methyl-N'-propyl- urea
[0295] Preparation 8:
N-[3-(7-Hydroxy-1-naphthyl)propyl]acetamide
[0296] Preparation 9:
N-[2-(7-Hydroxy-1-naphthyl)ethyl]-3-butenamide
[0297] Preparation 10:
N-[3-(7-Hydroxy-1-naphthyl)propyl]-1-cyclohexanecar- boxamide
[0298] Preparation 11:
N-[2-(2-Hydroxy-1-naphthyl)ethyl]-2,2,2-trifluoroac- etamide
[0299] Preparation 12:
N-[2-(2-Hydroxy-1-naphthyl)-1-methylethyl]propanami- de
[0300] Preparation 13:
N-[2-(7-Hydroxy-3-phenyl-1-naphthyl)ethyl]acetamide
[0301] Preparation 14:
N-[2-(3-Benzoyl-7-hydroxy-1-naphthyl)ethyl]-N'-prop- ylurea
[0302] Preparation 15:
N-{2-[3-(Cyclopropylmethyl)-7-hydroxy-1-naphthyl]et-
hyl}acetamide
[0303] Preparation 16:
N-[3-(5-Hydroxybenzo[b]furan-3-yl)propyl]acetamide
[0304] Preparation 17:
N-Methyl-4-(5-hydroxybenzo[b]furan-3-yl)butanamide
[0305] Preparation 18:
N-[2-(5-Hydroxybenzo[b]furan-3-yl)ethyl]acetamide
[0306] Preparation 19:
N-[(2-Benzyl-5-hydroxybenzo[b]thiophen-3-yl)methyl]- acetamide
[0307] Preparation 20:
N-[2-(5-Hydroxythieno[3,2-b]pyridin-3-yl)ethyl]acet- amide
[0308] Preparation 21:
N-[2-(5-Hydroxy-1H-3-indolyl)ethyl]benzamide
[0309] Preparation 22:
N-{2-[2-(4-Fluorobenzyl)-5-hydroxy-1-methyl-1H-pyrr-
olo[2,3-b]pyridin-3-yl]ethyl}acetamide
[0310] Preparation 23:
N-[2-(2-Benzyl-5-hydroxybenzo[b]furan-3-yl)ethyl]-1-
-cyclopropanecarboxamide
[0311] Preparation 24:
N-[(6-Hydroxy-3,4-dihydro-2H-3-chromenyl)methyl]ace- tamide
[0312] Preparation 25:
N-[2-(6-Hydroxy-3,4-dihydro-2H-4-chromenyl)ethyl]-2-
-phenylacetamide
[0313] Preparation 26:
N-[(6-Hydroxy-2-phenyl-2H-3-chromenyl)methyl]acetam- ide
[0314] Preparation 27:
N-[(6-Hydroxy-2-phenyl-2H-3-chromenyl)methyl]butana- mide
[0315] Preparation 28:
N-[2-(6-Hydroxy-3,4-dihydro-2H-4-thiochromenyl)ethy-
l]acetamide
[0316] Preparation 29:
N-[2-(7-Hydroxy-1,4-benzodioxin-2-yl)ethyl-N'-propy- lurea
[0317] Preparation 30:
N-[2-(7-Hydroxy-2,3-dihydro-1,4-benzodioxin-2-yl)et-
hyl]acetamide
[0318] Preparation 31:
N-[2-(6-Hydroxy-2,3-dihydro-1,4-benzodioxin-5-yl)et-
hyl]acetamide
[0319] Preparation 32:
N-[(9-Hydroxy-2,3-dihydro-1H-benzo[f]chromen-2-yl)m-
ethyl]-2-cyclopropylacetamide
[0320] Preparation 33:
N-Cyclopropyl-N'-(4-hydroxy-2,3-dihydro-1H-2-phenal-
enyl)thiourea
[0321] Preparation 34:
N-Cyclobutyl-3-hydroxy-4,5-dihydro-3H-benzo[cd]isob-
enzofuran-4-carboxamide
[0322] Preparation 35:
N-{2-[7-Hydroxy-3-naphthyl-1-naphthyl]ethyl}heptana- mide
[0323] Preparation 36:
N-[2-(7-Hydroxy-1,2,3,4-tetrahydro-1-naphthyl)ethyl- ]acetamide
[0324] Preparation 37:
N-[2-(6-Hydroxy-2,3-dihydro-1H-1-indenyl)ethyl]acet- amide
[0325] Preparation 38:
N-Cyclohexyl-4-(7-chloro-1-naphthyl)butanamide
[0326] Chlorine (10 mmol) is bubbled into dichlorophenylphosphine
at a flow rate such that the reaction temperature is maintained
between 70 and 80.degree. C. After all the chlorine has been added,
the phenylphosphine tetrachloride so obtained is a pale yellow
liquid. 10 mmol of the product obtained in Preparation 5 are added
all at once and the reaction mixture is heated at 160.degree. C.
overnight. After cooling, the solution is poured into a water/ice
mixture (20 ml) and is neutralised with a 50% aqueous solution of
sodium hydroxide. After extraction with ether, the organic phases
are dried and concentrated under reduced pressure to yield a
residue, which is chromatographed on silica gel to obtain the pure
title product.
[0327] In Preparation 39, the procedure is as in Preparation 38,
but the appropriate starting compound is used.
[0328] Preparation 39:
N-[(6-Chloro-3,4-dihydro-2H-3-chromenyl)methyl]acet- amide
[0329] Starting compound: Preparation 24
[0330] Preparation 40:
N-[2-(7-Bromo-1-naphthyl)ethyl]-2-phenylacetamide
[0331] Triphenylphosphine (10 mmol) and acetonitrile (70 ml) are
poured into a 150 ml three-necked flask equipped with a bromine
funnel, a condenser surmounted by a tube filled with calcium
chloride and a mechanical stirrer. The solution is cooled with the
aid of an ice bath, with stirring, and bromine is added (10 mmol).
At the end of the addition, the ice bath is removed and the product
obtained in Preparation 2 (8 mmol) is then added. The reaction
mixture is stirred at 60-70.degree. C. until the starting compound
has disappeared (monitored by TLC). At the end of the reaction, the
mixture is filtered and the filtrate is then concentrated under
reduced pressure. The residue is taken up in ethyl acetate, washed
with water and then with saturated potassium hydrogen carbonate
solution and once again with water, and is then dried over
magnesium sulphate and concentrated under reduced pressure. The
residue is filtered through silica gel to yield the title
product.
[0332] In Preparations 41 to 72.1, the procedure is as in
Preparation 40, starting from the appropriate reactant.
[0333] Preparation 41:
N-Cyclopropylmethyl-2-(7-bromo-1-naphthyl)acetamide
[0334] Starting compound: Preparation 5
[0335] Preparation 42:
N-[2-(7-Bromo-1-naphthyl)ethyl]-N-methyl-N'-propylu- rea
[0336] Starting compound: Preparation 7
[0337] Preparation 43:
N-[3-(7-Bromo-1-naphthyl)propyl]-1-cyclohexanecarbo- xamide
[0338] Starting compound: Preparation 10
[0339] Preparation 44:
N-[2-(2-Bromo-1-naphthyl)ethyl]-2,2,2-trifluoroacet- amide
[0340] Starting compound: Preparation 11
[0341] Preparation 45:
N-[2-(3-Benzoyl-7-bromo-1-naphthyl)ethyl]-N'-propyl- urea
[0342] Starting compound: Preparation 14
[0343] Preparation 46:
N-[3-(5-Bromobenzo[b]furan-3-yl)propyl]acetamide
[0344] Starting compound: Preparation 16
[0345] Preparation 47:
N-[(2-Benzyl-5-bromobenzo[b]thiophen-3-yl)methyl]ac- etamide
[0346] Starting compound: Preparation 19
[0347] Preparation 48:
N-[2-(5-Bromo-2-(4-fluorobenzyl)-1-methyl-1H-pyrrol-
o[2,3-b]pyridin-3-yl)ethyl]acetamide
[0348] Starting compound: Preparation 22
[0349] Preparation 49:
N-[2-(6-Bromo-3,4-dihydro-2H-4-chromenyl)ethyl]-2-p-
henylacetamide
[0350] Starting compound: Preparation 25
[0351] Preparation 50:
N-[(6-Bromo-2-phenyl-2H-3-chromenyl)methyl]acetamid- e
[0352] Starting compound: Preparation 26
[0353] Preparation 51:
N-[2-(6-Bromo-3,4-dihydro-2H-4-thiochromenyl)ethyl]- acetamide
[0354] Starting compound: Preparation 28
[0355] Preparation 52:
N-[2-(7-Bromo-1,4-benzodioxin-2-yl)ethyl]-N'-propyl- urea
[0356] Starting compound: Preparation 29
[0357] Preparation 53:
N-[2-(6-Bromo-2,3-dihydro-1,4-benzodioxin-5-yl)ethy-
l]acetamide
[0358] Starting compound: Preparation 31
[0359] Preparation 54:
N-[(9-Bromo-2,3-dihydro-1H-benzo[f]chromen-2-yl)met-
hyl]-2-cyclopropylacetamide
[0360] Starting compound: Preparation 32
[0361] Preparation 55:
N-(4-Bromo-2,3-dihydro-1H-2-phenalenyl)-N'-cyclopro-
pylthiourea
[0362] Starting compound: Preparation 33
[0363] Preparation 56:
N-Cyclobutyl-6-bromo-4,5-dihydro-3H-benzo[cd]isoben-
zofuran-4-carboxamide
[0364] Starting compound: Preparation 34
[0365] Preparation 57:
N-[2-(7-Bromo-3-naphthyl-1-naphthyl)ethyl]heptanami- de
[0366] Starting compound: Preparation 35
[0367] Preparation 58: N-[2-(7-Bromo-1-naphthyl)ethyl]acetamide
[0368] Starting compound: Preparation 1
[0369] Preparation 59:
N-[2-(7-Bromo-1-naphthyl)ethyl]-3-butenamide
[0370] Starting compound: Preparation 9
[0371] Preparation 60:
N-[2-(7-Bromo-1-naphthyl)ethyl]-2-bromoacetamide
[0372] Starting compound: Preparation 3
[0373] Preparation 61:
N-[2-(7-Bromo-8-hexyl-1-naphthyl)ethyl]-2-phenylace- tamide
[0374] Starting compound: Preparation 4
[0375] Preparation 62:
N-[3-(7-Bromo-1-naphthyl)propyl]acetamide
[0376] Starting compound: Preparation 8
[0377] Preparation 63:
N-[2-(2-Bromo-1-naphthyl)-1-methylethyl]propanamide
[0378] Starting compound: Preparation 12
[0379] Preparation 64:
N-{2-[7-Bromo-3-(cyclopropylmethyl)-1-naphthyl]ethy-
l}acetamide
[0380] Starting compound: Preparation 15
[0381] Preparation 65:
N-Methyl-3-(5-bromobenzo[b]furan-3-yl)butanamide
[0382] Starting compound: Preparation 17
[0383] Preparation 66:
N-[2-(5-Bromothieno[3,2-b]pyridin-3-yl)ethyl]acetam- ide
[0384] Starting compound: Preparation 20
[0385] Preparation 67:
N-[2-(5-Bromo-1H-3-indolyl)ethyl]benzamide
[0386] Starting compound: Preparation 21
[0387] Preparation 68:
N-[2-(2-Benzyl-5-bromobenzo[b]furan-3-yl)ethyl]-1-c-
yclopropanecarboxamide
[0388] Starting compound: Preparation 23
[0389] Preparation 69:
N-[(6-Bromo-2-phenyl-2H-3-chromenyl)methyl]butanami- de
[0390] Starting compound: Preparation 27
[0391] Preparation 70:
N-[2-(6-Bromo-2,3-dihydro-1H-1-indenyl)ethyl]acetam- ide
[0392] Starting compound: Preparation 37
[0393] Preparation 71:
N-[2-(7-Bromo-3-phenyl-1-naphthyl)ethyl]acetamide
[0394] Starting compound: Preparation 13
[0395] Preparation 72:
N-[2-(5-Bromobenzo[b]furan-3-yl)ethyl]acetamide
[0396] Starting compound: Preparation 18
[0397] Preparation 72.1:
N-[2-7-Bromo-1,2,3,4-tetrahydro-1-naphthyl)ethyl]- acetamide
[0398] Starting compound: Preparation 36
[0399] Preparation 73:
N-[2-(7-Iodo-1-naphthyl)ethyl]-2-phenylacetamide
[0400] A mixture of the product obtained in Preparation 40 (2
mmol), potassium iodide (30 mmol) and copper(I) iodide (10 mmol) in
hexamethylphosphoramide (6 ml) is heated at 150-160.degree. C.,
with stirring, under a nitrogen atmosphere until 90% conversion has
been achieved (monitored by TLC). Then, dilute hydrochloric acid,
and then ether, are added and the mixture is then filtered to
remove the insoluble copper(I) salts. The organic phase is
separated off, washed with sodium sulphite solution and with water,
dried over magnesium sulphate and evaporated to yield a residue
which is chromatographed on silica gel to yield the title
product.
[0401] In Preparations 74 to 108 the procedure is as in Preparation
73, but the product of Preparation 40 is replaced by the
appropriate substrate.
[0402] Preparation 74:
N-Cyclopropylmethyl-2-(7-iodo-1-naphthyl)acetamide
[0403] Starting compound: Preparation 41
[0404] Preparation 75:
N-[2-(7-Iodo-1-naphthyl)ethyl]-N-methyl-N'-propylur- ea
[0405] Starting compound: Preparation 42
[0406] Preparation 76:
N-[3-(7-Iodo-1-naphthyl)propyl]-1-cyclohexanecarbox- amide
[0407] Starting compound: Preparation 43
[0408] Preparation 77:
N-[2-(2-Iodo-1-naphthyl)ethyl]-2,2,2-trifluoroaceta- mide
[0409] Starting compound: Preparation 44
[0410] Preparation 78:
N-[2-(3-Benzoyl-7-iodo-1-naphthyl)ethyl]-N'-propylu- rea
[0411] Starting compound: Preparation 45
[0412] Preparation 79:
N-[3-(5-Iodobenzo[b]furan-3-yl)propyl]acetamide
[0413] Starting compound: Preparation 46
[0414] Preparation 80:
N-[(2-Benzyl-5-iodobenzo[b]thiophen-3-yl)methyl]ace- tamide
[0415] Starting compound: Preparation 47
[0416] Preparation 81:
N-[2-(5-Iodo-2-(4-fluorobenzyl)-1-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-yl)-ethyl]acetamide
[0417] Starting compound: Preparation 48
[0418] Preparation 82:
N-[(6-Iodo-3,4-dihydro-2H-3-chromenyl)methyl]acetam- ide
[0419] Starting compound: Preparation 39
[0420] Preparation 83:
N-[2-(6-Iodo-3,4-dihydro-2H-4-chromenyl)ethyl]-2-ph-
enylacetamide
[0421] Starting compound: Preparation 49
[0422] Preparation 84:
N-[(6-Iodo-2-phenyl-2H-3-chromenyl)methyl]acetamide
[0423] Starting compound: Preparation 50
[0424] Preparation 85:
N-[2-(6-Iodo-3,4-dihydro-2H-4-thiochromenyl)ethyl]a- cetamide
[0425] Starting compound: Preparation 51
[0426] Preparation 86:
N-[2-(7-Iodo-1,4-benzodioxin-2-yl)ethyl]-N'-propylu- rea
[0427] Starting compound: Preparation 52
[0428] Preparation 87:
N-[2-(6-Iodo-2,3-dihydro-1,4-benzodioxin-5-yl)ethyl- ]acetamide
[0429] Starting compound: Preparation 53
[0430] Preparation 88:
N-[(9-Iodo-2,3-dihydro-1H-benzo[f]chromen-2-yl)meth-
yl]-2-cyclopropyl-acetamide
[0431] Starting compound: Preparation 54
[0432] Preparation 89:
N-(4-Iodo-2,3-dihydro-1H-2-phenalenyl)-N'-cycloprop- ylthiourea
[0433] Starting compound: Preparation 55
[0434] Preparation 90:
N-Cyclobutyl-6-iodo-4,5-dihydro-3H-benzo[cd]isobenz-
ofuran-4-carboxamide
[0435] Starting compound: Preparation 56
[0436] Preparation 91:
N-[2-(7-Iodo-3-naphthyl-1-naphthyl)ethyl]heptanamid- e
[0437] Starting compound: Preparation 57
[0438] Preparation 92: N-[2-(7-Iodo-1-naphthyl)ethyl]acetamide
[0439] Starting compound: Preparation 58
[0440] Preparation 93:
N-[2-(7-Iodo-1-naphthyl)ethyl]-3-butenamide
[0441] Starting compound: Preparation 59
[0442] Preparation 94:
N-[2-(7-Iodo-1-naphthyl)ethyl]-2-bromoacetamide
[0443] Starting compound: Preparation 60
[0444] Preparation 95:
N-[2-(7-Iodo-8-hexyl-1-naphthyl)ethyl]-2-phenylacet- amide
[0445] Starting compound: Preparation 61
[0446] Preparation 96:
N-Cyclohexyl-4-(7-iodo-1-naphthyl)butanamide
[0447] Starting compound: Preparation 38
[0448] Preparation 97: N-[3-(7-Iodo-1-naphthyl)propyl]acetamide
[0449] Starting compound: Preparation 62
[0450] Preparation 98:
N-[2-(2-Iodo-1-naphthyl)-1-methylethyl]propanamide
[0451] Starting compound: Preparation 63
[0452] Preparation 99:
N-{2-[7-Iodo-3-(cyclopropylmethyl)-1-naphthyl]ethyl- }acetamide
[0453] Starting compound: Preparation 64
[0454] Preparation 100:
N-Methyl-4-(5-iodobenzo[b]furan-3-yl)butanamide
[0455] Starting compound: Preparation 65
[0456] Preparation 101:
N-[2-(5-Iodothieno[3,2-b]pyridin-3-yl)ethyl]acetam- ide
[0457] Starting compound: Preparation 66
[0458] Preparation 102:
N-[2-(5-Iodo-1H-3-indolyl)ethyl]benzamide
[0459] Starting compound: Preparation 67
[0460] Preparation 103:
N-[2-(2-Benzyl-5-iodobenzo[b]furan-3-yl)ethyl]-1-c-
yclopropanecarboxamide
[0461] Starting compound: Preparation 68
[0462] Preparation 104:
N-[(6-Iodo-2-phenyl-2H-3-chromenyl)methyl]butanami- de
[0463] Starting compound: Preparation 69
[0464] Preparation 105:
N-[2-(6-Iodo-2,3-dihydro-1H-1-indenyl)ethyl]acetam- ide
[0465] Starting compound: Preparation 70
[0466] Preparation 106:
N-[2-(7-Iodo-3-phenyl-1-naphthyl)ethyl]acetamide
[0467] Starting compound: Preparation 71
[0468] Preparation 107:
N-[2-(7-Iodo-1,2,3,4-tetrahydro-1-naphthyl)ethyl]a- cetamide
[0469] Starting compound: Preparation 72.1
[0470] Preparation 108:
N-[2-(5-Iodobenzo[b]furan-3-yl)ethyl]acetamide
[0471] Starting compound: Preparation 72
[0472] Preparation 109:
N-[2-(7-Amino-1-naphthyl)ethyl]-2-phenylacetamide
[0473] Step A:
N-[2-(7-Vinyl-1-naphthyl)ethyl]-2-phenylacetamide
[0474] 15 mmol of the product obtained in Preparation 73, 16 mmol
of vinyltributyltin and 0.43 mmol of
tetrakis(triphenylphosphine)palladium are heated in 30 ml of
N-methylpyrrolidinone at 110.degree. C. for 3 hours, with stirring.
After evaporating off the solvent, the residue is taken up in 20 ml
of dichloromethane and treated with 10% aqueous potassium fluoride
solution. After extraction, concentration under reduced pressure
and chromatography on silica gel, the pure title product is
obtained.
[0475] Step B:
N-[2-(7-Formyl-1-naphthyl)ethyl]-2-phenylacetamide
[0476] To a solution of 10 mmol of the product obtained in Step A
in a mixture of 50 ml of dioxane and 25 ml of water there are
added, at ambient temperature, 1.10 g of osmium tetroxide in
2-methyl-2-propanol and then 8.70 g of sodium periodate. After
stirring overnight at ambient temperature, the suspension is
filtered and the filtrate is concentrated under reduced pressure.
The residue obtained is taken up in dichloromethane. The organic
phase is washed with water, dried and evaporated. The residue is
purified by chromatography on silica gel to yield the title
product.
[0477] Step C: 8-{2-[(2-Phenylacetyl)amino]ethyl}-2-naphthoic
Acid
[0478] 2.7 g of potassium permanganate in 50 ml of an acetone/water
mixture (50/50) are added, at ambient temperature, to a solution of
6.88 mmol of the product obtained in Step B in 30 ml of acetone.
The solution is stirred for 2 hours at ambient temperature and is
then filtered. The filtrate is concentrated under reduced pressure
and chromatographed on silica gel to yield the title product.
[0479] Step D:
8-{2-[(2-Phenylacetyl)amino]ethyl}-2-naphthalenecarbonyl
Chloride
[0480] 5 mmol of the product obtained in Step C are dissolved in 40
ml of thionyl chloride. After stirring under an inert atmosphere
for 1 hour, the thionyl chloride is evaporated off under reduced
pressure to yield the title product.
[0481] Step E:
N-[2-(7-Amino-1-naphthyl)ethyl]-2-phenylacetamide
[0482] A solution of the product obtained in Step D (20 mmol) in
dichloromethane (30 ml) containing tetrabutylammonium bromide (20
mg) is cooled in an ice bath. After adding sodium azide (24 mmol)
dissolved in 5 ml of water, the solution is stirred vigorously at
0.degree. C. for 2 hours. The organic phase is separated off,
washed with water (2.times.5 ml) and dried over magnesium sulphate.
After filtration, trifluoroacetic acid (30 mmol) is added and the
solution is stirred under reflux for 60 hours. After cooling, the
organic phase is washed with saturated sodium hydrogen carbonate
solution (2.times.5 ml) and is concentrated under reduced pressure.
The residue is then taken up in methanol (20 ml); water (80 ml) and
then potassium carbonate (30 mmol) are added. After stirring at
ambient temperature for 20 hours, the reaction mixture is
concentrated under reduced pressure to a volume of about 60 ml and
is then extracted 3 times with ether (3.times.50 ml). After drying
over sodium sulphate, the organic phase is filtered and then
evaporated under reduced pressure. The residue is chromatographed
on silica gel to yield the title product.
[0483] In Preparations 110 to 134 the procedure is as in Example
109, starting from the appropriate substrate.
[0484] Preparation 110:
N-[2-(7-Amino-1-naphthyl)ethyl]-2-bromoacetamide
[0485] Starting compound: Preparation 94
[0486] Preparation 111:
N-[2-(7-Amino-8-hexyl-1-naphthyl)ethyl]-2-phenylac- etamide
[0487] Starting compound: Preparation 95
[0488] Preparation 112:
N-Cyclohexyl-4-(7-amino-1-naphthyl)butanamide
[0489] Starting compound: Preparation 96
[0490] Preparation 113:
N-[3-(7-Amino-1-naphthyl)propyl]acetamide
[0491] Starting compound: Preparation 97
[0492] Preparation 114:
N-[2-(2-Amino-1-naphthyl)-1-methylethyl]propanamid- e
[0493] Starting compound Preparation 98
[0494] Preparation 115:
N-[2-(7-Amino-3-benzoyl-1-naphthyl)ethyl]-N'-propy- lurea
[0495] Starting compound: Preparation 78
[0496] Preparation 116:
N-[2-(7-Amino-1-naphthyl)ethyl]-3-butenamide
[0497] Starting compound: Preparation 93
[0498] Preparation 117:
N-[2-(7-Amino-1-naphthyl)ethyl]acetamide
[0499] Starting compound: Preparation 92
[0500] Preparation 118:
N-{2-[7-Amino-3-(cyclopropylmethyl)-1-naphthyl]eth-
yl}acetamide
[0501] Starting compound: Preparation 99
[0502] Preparation 119:
N-Methyl-4-(5-aminobenzo[b]furan-3-yl)butanamide
[0503] Starting compound: Preparation 100
[0504] Preparation 120:
N-[2-(5-Aminothieno[3,2-b]pyridin-3-yl)ethyl]aceta- mide
[0505] Starting compound: Preparation 101
[0506] Preparation 121:
N-[2-(5-Amino-1H-3-indolyl)ethyl]benzamide
[0507] Starting compound: Preparation 102
[0508] Preparation 122:
N-{2-[5-Amino-2-(4-fluorobenzyl)-1-methyl-1H-pyrro-
lo[2,3-b]pyridin-3-yl]ethyl}acetamide
[0509] Starting compound: Preparation 81
[0510] Preparation 123:
N-[2-(5-Amino-2-benzylbenzo[b]furan-3-yl)ethyl]-1--
cyclopropanecarboxamide
[0511] Starting compound: Preparation 103
[0512] Preparation 124:
N-[(6-Amino-3,4-dihydro-2H-3-chromenyl)methyl]acet- amide
[0513] Starting compound: Preparation 82
[0514] Preparation 125:
N-[(6-Amino-2-phenyl-2H-3-chromenyl)methyl]butanam- ide
[0515] Starting compound: Preparation 104
[0516] Preparation 126:
N-[2-(6-Amino-2,3-dihydro-1,4-benzodioxin-5-yl)eth-
yl]acetamide
[0517] Starting compound: Preparation 87
[0518] Preparation 127:
N-[(9-Amino-2,3-dihydro-1H-benzo[f]chromen-2-yl)me-
thyl]-2-cyclopropylacetamide
[0519] Starting compound: Preparation 88
[0520] Preparation 128:
N-(4-Amino-2,3-dihydro-1H-2-phenalenyl)-N'-cyclopr-
opylthiourea
[0521] Starting compound: Preparation 89
[0522] Preparation 129:
N-[2-(7-Amino-3-phenyl-1-naphthyl)ethyl]acetamide
[0523] Starting compound: Preparation 106
[0524] Preparation 130:
N-Cyclobutyl-6-amino-4,5-dihydro-3H-benzo[cd]isobe-
nzofuran-4-carboxamide
[0525] Starting compound: Preparation 90
[0526] Preparation 131:
N-[2-(7-Amino-3-naphthyl-1-naphthyl)ethyl]heptanam- ide
[0527] Starting compound: Preparation 91
[0528] Preparation 132:
N-[2-(5-Aminobenzo[b]furan-3-yl)ethyl]acetamide
[0529] Starting compound: Preparation 108
[0530] Preparation 133:
N-[2-(7-Amino-1,2,3,4-tetrahydro-1-naphthyl)ethyl]- acetamide
[0531] Starting compound: Preparation 107
[0532] Preparation 134:
N-[2-(6-Amino-2,3-dihydro-1H-1-indenyl)ethyl]aceta- mide
[0533] Starting compound: Preparation 105
[0534] Preparations 135 to 145 are obtained by proceeding as in
Preparation 1, starting from the appropriate substrate.
[0535] Preparation 135:
N-[2-(7-Hydroxy-1-naphthyl)ethyl]-2-furamide
[0536] Preparation 136:
N-[2-(7-Hydroxy-1-naphthyl)ethyl]benzamide
[0537] Preparation 137:
N-[2-(7-Hydroxy-1-naphthyl)ethyl]cyclopropanecarbo- xamide
[0538] Preparation 138:
N-[2-(5-Hydroxy-1-benzofuran-3-yl)ethyl]benzamide
[0539] Preparation 139:
N-[2-(5-Hydroxy-1-benzofuran-3-yl)ethyl]-2-furamid- e
[0540] Preparation 140:
N-[2-(5-Hydroxy-1-benzofuran-3-yl)ethyl]cyclopropa-
necarboxamide
[0541] Preparation 141:
N-[2-(5-Hydroxy-1-benzothiophen-3-yl)ethyl]cyclopr-
opanecarboxamide
[0542] Preparation 142:
N-[2-(5-Hydroxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethy- l]acetamide
[0543] Preparation 143:
N-[2-(5-Hydroxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethy-
l]cyclopropanecarboxamide
[0544] Preparation 144:
N-[2-(5-Hydroxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethy- l]benzamide
[0545] Preparation 145:
N-[2-(5-Hydroxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethy-
l]-2-furamide
[0546] Preparation 146:
N-[2-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)ethyl]- acetamide
[0547] The procedure is as in Preparation 40, starting from the
compound obtained in Preparation 142.
[0548] Preparation 147:
N-[2-(5-Iodo-1H-pyrrolo[2,3-b]pyridin-3-yl)ethyl]a- cetamide
[0549] The procedure is as in Preparation 73, starting from the
compound obtained in Preparation 146.
[0550] Preparation 148:
N-[2-(5-Amino-1-pyrrolo[2,3-b]pyridin-3-yl)ethyl]a- cetamide
[0551] The procedure is as in Preparation 109, starting from the
compound obtained in Preparation 147.
[0552] Preparation 149:
N-[2-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)ethyl]- -2-furamide
[0553] The procedure is as in Preparation 40, starting from the
compound obtained in Preparation 145.
[0554] Preparation 150:
N-[2-(5-Iodo-1H-pyrrolo[2,3-b]pyridin-3-yl)ethyl]-- 2-furamide
[0555] The procedure is as in Preparation 73, starting from the
compound obtained in Preparation 149.
[0556] Preparation 151:
N-[2-(5-Amino-1H-pyrrolo[2,3-b]pyridin-3-yl)ethyl]- -2-furamide
[0557] The procedure is as in Preparation 109, starting from the
compound obtained in Preparation 150.
[0558] Preparation 152:
N-[2-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)ethyl]- benzamide
[0559] The procedure is as in Preparation 40, starting from the
compound obtained in Preparation 144.
[0560] Preparation 153:
N-[2-(5-Iodo-1-pyrrolo[2,3-b]pyridin-3-yl)ethyl]be- nzamide
[0561] The procedure is as in Preparation 73, starting from the
compound obtained in Preparation 152.
[0562] Preparation 154:
N-[2-(5-Amino-1-pyrrolo[2,3-b]pyridin-3-yl)ethyl]b- enzamide
[0563] The procedure is as in Preparation 109, starting from the
compound obtained in Preparation 153.
[0564] Preparation 155:
N-[2-(5-Bromo-1-pyrrolo[2,3-b]pyridin-3-yl)ethyl]c-
yclopropanecarboxamide
[0565] The procedure is as in Preparation 40, starting from the
compound obtained in Preparation 143.
[0566] Preparation 156:
N-[2-(5-Iodo-1-pyrrolo[2,3-b]pyridin-3-yl)ethyl]cy-
clopropanecarboxamide
[0567] The procedure is as in Preparation 73, starting from the
compound obtained in Preparation 155.
[0568] Preparation 157:
N-[2-(5-Amino-1-pyrrolo[2,3-b]pyridin-3-yl)ethyl]c-
yclopropanecarboxamide
[0569] The procedure is as in Preparation 109, starting from the
compound obtained in Preparation 156.
[0570] Preparation 158:
N-[2-(5-Hydroxy-1-pyrrolo[3,2-b]pyridin-3-yl)ethyl-
]cyclopropanecarboxamide
[0571] The procedure is as in Preparation 1.
[0572] Preparation 159:
N-[2-(5-Bromo-1-pyrrolo[3,2-b]pyridin-3-yl)ethyl]c-
yclopropanecarboxamide
[0573] The procedure is as in Preparation 40, starting from the
compound obtained in Preparation 158.
[0574] Preparation 160:
N-[2-(5-Iodo-1-pyrrolo[3,2-b]pyridin-3-yl)ethyl]cy-
clopropanecarboxamide
[0575] The procedure is as in Preparation 73, starting from the
compound obtained in Preparation 159.
[0576] Preparation 161:
N-[2-(5-Amino-1-pyrrolo[3,2-b]pyridin-3-yl)ethyl]c-
yclopropanecarboxamide
[0577] The procedure is as in Preparation 109, starting from the
compound obtained in Preparation 160.
[0578] Preparation 162:
N-[2-(5-Hydroxy-1-pyrrolo[3,2-b]pyridin-3-yl)ethyl- ]acetamide
[0579] The procedure is as in Preparation 1.
[0580] Preparation 163:
N-[2-(5-Bromo-1H-pyrrolo[3,2-b]pyridin-3-yl)ethyl]- acetamide
[0581] The procedure is as in Preparation 40, starting from the
compound obtained in Preparation 162.
[0582] Preparation 164:
N-[2-(5-Iodo-1-pyrrolo[3,2-b]pyridin-3-yl)ethyl]ac- etamide
[0583] The procedure is as in Preparation 73, starting from the
compound obtained in Preparation 163.
[0584] Preparation 165:
N-[2-(5-Amino-1-pyrrolo[3,2-b]pyridin-3-yl)ethyl]a- cetamide
[0585] The procedure is as in Preparation 109, starting from the
compound obtained in Preparation 164.
[0586] Preparation 166:
N-[2-(5-Bromo-1-benzofuran-3-yl)ethyl]cyclopropane- carboxamide
[0587] The procedure is as in Preparation 40, starting from the
compound obtained in Preparation 140.
[0588] Preparation 167:
N-[2-(5-Iodo-1-benzofuran-3-yl)ethyl]cyclopropanec- arboxamide
[0589] The procedure is as in Preparation 73, starting from the
compound obtained in Preparation 166.
[0590] Preparation 168:
N-[2-(5-Amino-1-benzofuran-3-yl)ethyl]cyclopropane- carboxamide
[0591] The procedure is as in Preparation 109, starting from the
compound obtained in Preparation 167.
[0592] Preparation 169:
N-[2-(5-Hydroxy-1-benzothiophen-3-yl)ethyl]benzami- de
[0593] The procedure is as in Preparation 1.
[0594] Preparation 170:
N-[2-(5-Bromo-1-benzothiophen-3-yl)ethyl]benzamide
[0595] The procedure is as in Preparation 40, starting from the
compound obtained in Preparation 169.
[0596] Preparation 171:
N-[2-(5-Iodo-1-benzothiophen-3-yl)ethyl]benzamide
[0597] The procedure is as in Preparation 73, starting from the
compound obtained in Preparation 170.
[0598] Preparation 172:
N-[2-(5-Amino-1-benzothiophen-3-yl)ethyl]benzamide
[0599] The procedure is as in Preparation 109, starting from the
compound obtained in Preparation 171.
[0600] Preparation 173:
N-[2-(7-Bromo-1-naphthyl)ethyl]-2-furamide
[0601] The procedure is as in Preparation 40, starting from the
compound obtained in Preparation 135.
[0602] Preparation 174:
N-[2-(7-Iodo-1-naphthyl)ethyl]-2-furamide
[0603] The procedure is as in Preparation 73, starting from the
compound obtained in Preparation 173.
[0604] Preparation 175:
N-[2-(5-Bromo-1-benzofuran-3-yl)ethyl]benzamide
[0605] The procedure is as in Preparation 40, starting from the
compound obtained in Preparation 138.
[0606] Preparation 176:
N-[2-(5-Iodo-1-benzofuran-3-yl)ethyl]benzamide
[0607] The procedure is as in Preparation 73, starting from the
compound obtained in Preparation 176.
EXAMPLE 1
N-{8-[2-([2-Phenylacetyl]amino)ethyl]-2-naphthyl}butanamide
[0608] A solution of butanoic acid chloride (11 mmol) dissolved in
ether (5 ml) is added dropwise to a solution of the product
obtained in Preparation 109 (10 mmol) in ether (10 ml) and
triethylamine (2 ml). The solution is stirred at ambient
temperature until the amine has disappeared (monitored by TLC). At
the end of the reaction, the organic phase is washed with water,
dried, concentrated under reduced pressure and chromatographed on
silica gel to yield the title product.
EXAMPLE 2
N-{2-[7-{[(Cyclohexylamino)carbonyl]amino}-1-naphthyl]ethyl}-2-phenylaceta-
mide
[0609] A solution of cyclohexyl isocyanate in dichloromethane (5
ml) is added to a solution of the product obtained in Preparation
109 (10 mmol) in dichloromethane (10 ml). Stirring is carried out
at ambient temperature until the starting amine has disappeared
(monitored by TLC); the reaction mixture is then evaporated and
concentrated under reduced pressure and is chromatographed on
silica gel to yield the title product.
EXAMPLE 3
N-{2-[7-([Anilinocarbothioyl]amino)-1-naphthyl]ethyl}-2-phenylacetamide
[0610] The procedure is as in Example 2, but the cyclohexyl
isocyanate is replaced by phenyl isothiocyanate to obtain the title
product.
[0611] In Examples 4 to 16 the procedure is as in Example 1,
starting from appropriate reactants.
EXAMPLE 4
N-(8-{2-[(2-Bromoacetyl)amino]ethyl}-2-naphthyl)-1-cyclohexanecarboxamide
[0612] Starting compound: Preparation 110
EXAMPLE 5
N-{1-Hexyl-8-[2-([2-phenylacetyl]amino)ethyl]-2-naphthyl}benzamide
[0613] Starting compound: Preparation 111
EXAMPLE 6
N-{6-Benzoyl-8-[2-{[(propylamino)carbonyl]amino}ethyl]-2-naphthyl}-2,2-dim-
ethylpropanamide
[0614] Starting compound: Preparation 115
EXAMPLE 7
N-{3-[4-(Methylamino)-4-oxobutyl]benzo[b]furan-5-yl}-3-butynamide
[0615] Starting compound: Preparation 119
EXAMPLE 8
N-{3-[2-(Acetylamino)ethyl]-2-[4-fluorobenzyl]-1-methyl-1-pyrrolo-[2,3-b]p-
yridin-5-yl}-3-phenyl-2-propenamide
[0616] Starting compound: Preparation 122
EXAMPLE 9
N-{3-[(Acetylamino)methyl-3,4-dihydro-2H-6-chromenyl}-2-phenyl-propanamide
[0617] Starting compound: Preparation 124
EXAMPLE 10
N-{5-[2-(Acetylamino)ethyl]-2,3-dihydro-1,4-benzodioxin-6-yl}-hexanamide
[0618] Starting compound: Preparation 126
EXAMPLE 11
N-{2-[([2-Cyclopropylacetyl]amino)methyl]-2,3-dihydro-1H-benzo[f]-chromen--
9-yl}-4-(trifluoromethyl)benzamide
[0619] Starting compound: Preparation 127
EXAMPLE 12
N-{2-[([Cyclopropylamino]carbothioyl)amino]-2,3-dihydro-1H-4-phenalenyl}-4-
-ethoxybenzamide
[0620] Starting compound: Preparation 128
EXAMPLE 13
N-{8-[2-(Acetylamino)ethyl]-6-phenyl-2-naphthyl}-1-cyclopentane-carboxamid-
e
[0621] Starting compound: Preparation 129
EXAMPLE 14
N-Cyclobutyl-6-([2-cyclopropylacetyl)amino]-4,5-dihydro-3H-benzo[cd]-isobe-
nzofuran-4-carboxamide
[0622] Starting compound: Preparation 130
EXAMPLE 15
N-{8-[2-(Heptanoylamino)ethyl]-2,6-dinaphthyl}-2-butenamide
[0623] Starting compound: Preparation 131
EXAMPLE 16
N-{2-[6-(Acetylamino)-2,3-dihydro-1H-1-indenyl]ethyl}acetamide
[0624] Starting compound: Preparation 134
[0625] Examples 17 to 23 are obtained by proceeding as in Example
2, starting from appropriate reactants.
EXAMPLE 17
N-Cyclohexyl-4-{7-1(anilinocarbonyl)amino]-1-naphthyl}butanamide
[0626] Starting compound: Preparation 112
EXAMPLE 18
N-{1-Methyl-2-[2-{[([morpholinomethyl]amino)carbonyl]amino}-1-naphthyl]eth-
yl}propanamide
[0627] Starting compound: Preparation 114
EXAMPLE 19
N-{2-[7-{[(Benzylamino)carbonyl]amino}-3-(cyclopropylmethyl)-1-naphthyl]et-
hyl}acetamide
[0628] Starting compound: Preparation 118
EXAMPLE 20
N-{2-[5-{[(Allylamino)carbonyl]amino}thieno[3,2-b]pyridin-3-yl]ethyl}-acet-
amide
[0629] Starting compound: Preparation 120
EXAMPLE 21
N-{2-[2-Benzyl-5-{[(1-ethynylamino)carbonyl]amino}benzo[b]furan-3-yl]ethyl-
}-1-cyclopropanecarboxamide
[0630] Starting compound: Preparation 123
EXAMPLE 22:
N-{[6-{[([3-Methyl-2-butenyl]amino)carbonyl]amino}-2-phenyl-2H-
-3-chromenyl]methyl}butanamide
[0631] Starting compound: Preparation 125
EXAMPLE 23
N-[2-(7-{[(Cyclohexylamino)carbonyl]amino}-3-phenyl-1-naphthyl)-ethyl]acet-
amide
[0632] Starting compound: Preparation 129
[0633] In Examples 24 to 29 the procedure is as in Example 3,
starting from appropriate substrates.
EXAMPLE 24
N-{2-[7-{[(Isobutylamino)carbothioyl]amino}-1-naphthyl]ethyl}-2-bromoaceta-
mide
[0634] Starting compound: Preparation 110
EXAMPLE 25
N-{3-[7-{[([4-Methylbenzyl]amino)carbothioyl]amino}-1-naphthyl]-propyl}ace-
tamide
[0635] Starting compound: Preparation 113
EXAMPLE 26
N-Methyl-4-{5-[([1-ethynylamino]carbothioyl)amino]benzo[b]furan-3-yl}butan-
amide
[0636] Starting compound: Preparation 119
EXAMPLE 27
N-{2-[5-{[(Butylamino)carbothioyl]amino}-1H-3-indoly]ethyl}-benzamide
[0637] Starting compound: Preparation 121
EXAMPLE 28
N-{[9-([Anilinocarbothioyl]amino)-2,3-dihydro-1H-benzo[f]chromen-2-yl]meth-
yl}-2-cyclopropylacetamide
[0638] Starting compound: Preparation 127
EXAMPLE 29
N-Cyclobutyl-6-{[([2,3-dimethyl-2-butenyl]amino)carbothioyl]amino}-4,5-dih-
ydro-3H-benzo[cd]isobenzofuran-4-carboxamide
[0639] Starting compound: Preparation 130
EXAMPLE 30
N-Ethyl-8-{2-[(2-phenylacetyl)amino]ethyl}-2-naphthamide
[0640] The procedure is as in Preparation 109, but instead of
converting the acid chloride into an amine, it is treated with an
amine to yield the title amide according to the procedure described
below.
[0641] A solution of the product obtained in Step D of Preparation
109 (3.5 mmol) in ether (10 ml) is added, dropwise, to a solution
of ethylamine (4 mmol) in ether (10 ml) and triethylamine (2 ml),
maintained between 0 and 5.degree. C. using an ice bath. Stirring
is carried out at ambient temperature until the acid chloride has
disappeared and the reaction mixture is then poured into a mixture
of ice (10 g) and concentrated HCl (0.1 ml). The organic phase is
washed with water, dried over magnesium sulphate, concentrated
under reduced pressure and chromatographed on silica gel to yield
the title product.
[0642] In Examples 31 to 50 the procedure is as in Example 30, but
the ethylamine and the product of Step D of Preparation 109 are
replaced by appropriate substrates.
EXAMPLE 31
N,N-Diethyl-8-{2-[2-[(cyclopropylmethyl)amino]-2-oxoethyl}-2-naphthamide
[0643] Starting compound: Preparation 74
EXAMPLE 32
N-Phenyl-8-(2-{methyl[(propylamino)carbonyl]amino}ethyl)-2-naphthamide
[0644] Starting compound: Preparation 75
EXAMPLE 33
N-(1-Ethynyl)-8-{2-[(cyclohexylcarbonyl)amino]ethyl}-2-naphthamide
[0645] Starting compound: Preparation 76
EXAMPLE 34
N-Benzyl-1-{2-[(2,2,2-trifluoroacetyl)amino]ethyl}-2-naphthamide
[0646] Starting compound: Preparation 77
EXAMPLE 35
N-{2-13-Benzoyl-7-(morpholinocarbonyl)-1-naphthyl]ethyl}-N'-propylurea
[0647] Starting compound: Preparation 78
EXAMPLE 36
N,N-Diphenyl-3-[3-(acetylamino)propyl]benzo[b]furan-5-carboxamide
[0648] Starting compound: Preparation 79
EXAMPLE 37
N-Isopropyl-N-(2-propynyl)-3-[(acetylamino)methyl]-2-benzylbenzo[b]-thioph-
ene-5-carboxamide
[0649] Starting compound: Preparation 80
EXAMPLE 38
N,N-Diethyl-3-[2-(acetylamino)ethyl]-2-(4-fluorobenzyl)-1-methyl-1H-pyrrol-
o[2,3-b]pyridine-5-carboxamide
[0650] Starting compound: Preparation 81
EXAMPLE 39
Ethyl
2-{[(4-{2-[(2-phenylacetyl)amino]ethyl}-3,4-dihydro-2H-6-chromenyl)c-
arbonyl]amino}acetate
[0651] Starting compound: Preparation 83
EXAMPLE 40
N-Cyclohexyl-N-(1-ethynyl)-4-[2-(acetylamino)ethyl]-6-thiochroman-carboxam-
ide
[0652] Starting compound: Preparation 85
EXAMPLE 41
N-Benzyl-3-(2-{[(propylamino)carbonyl]amino}ethyl-1,4-benzodioxin-6-carbox-
amide
[0653] Starting compound: Preparation 86
EXAMPLE 42
N-(3-Methyl-2-butenyl)-2-{[(2-cyclopropylacetyl)amino]methyl}-2,3,6,10b-te-
trahydro-1-benzo[f]chromene-8-carboxamide
[0654] Starting compound: Preparation 88
EXAMPLE 43
N-[3-Phenyl-2-propenyl]-2-{[(cyclopropylamino)carbothioyl]amino}-2,3-dihyd-
ro-1H-4-phenalenecarboxamide
[0655] Starting compound: Preparation 89
EXAMPLE 44
N-Cyclobutyl-N-trityl-4,5-dihydro-3H-benzo[cd]isobenzofuran-4,6-dicarboxam-
ide
[0656] Starting compound: Preparation 90
EXAMPLE 45
Ethyl
2-1({8-[2-heptanoylamino)ethyl]-6-naphthyl-2-naphthyl}carbonyl)-amin-
o]acetate
[0657] Starting compound: Preparation 91
EXAMPLE 46
N-(1-Ethynyl)-8-{2-[(2-bromoacetyl)amino]ethyl}-2-naphthamide
[0658] Starting compound: Preparation 94
EXAMPLE 47
N-Phenyl-1-hexyl-8-{2-[(2-phenylacetyl)amino]ethyl}-2-naphthamide
[0659] Starting compound: Preparation 95
EXAMPLE 48
Ethyl
2-({[8-[2-(acetylamino)ethyl]-6-(cyclopropylmethyl)-2-naphthyl]-carb-
onyl}amino)acetate
[0660] Starting compound: Preparation 99
EXAMPLE 49
N-(1-Ethynyl)-2-benzyl-3-{2-[(cyclopropylcarbonyl)amino]ethyl}benzo-[b]fur-
an-5-carboxamide
[0661] Starting compound: Preparation 103
EXAMPLE 50
N-(1-Isopropyl-2-propynyl)-3-[(butynylamino)methyl]-2-phenyl-2H-6-chromene-
carboxamide
[0662] Starting compound: Preparation 104
EXAMPLE 51
N-Phenyl-8-(2-{methyl[(propylamino)carbothioyl]amino}ethyl)-2-naphthalenec-
arbothioamide
[0663] The product obtained in Example 32 is treated with
Lawesson's reagent to yield the title compound.
[0664] In Examples 52 to 57 the procedure is as in Example 51,
taking the appropriate starting substrate.
EXAMPLE 52
N-Benzyl-1-{2-[(2,2,2-trifluoroethanethioyl)amino]ethyl}-2-naphthalenecarb-
othioamide
[0665] Starting compound: Example 34
EXAMPLE 53
N,N-Diphenyl-3-[3-(ethanethioylamino)propyl]benzo[b]furan-5-carbothioamide
[0666] Starting compound: Example 36
EXAMPLE 54
N,N-Diethyl-3-[2-(ethanethioylamino)ethyl]-2-(4-fluorobenzyl)-1-methyl-1H--
pyrrolo[2,3-b]pyridine-5-carbothioamide
[0667] Starting compound: Example 38
EXAMPLE 55
N-Cyclohexyl-N-(1-ethynyl)-4-[2-(ethanethioylamino)ethyl]-6-thiochromancar-
bothioamide
[0668] Starting compound: Example 40
EXAMPLE 56
N-(3-Methyl-2-butenyl)-2-{([(2-cyclopropylethanethioyl)amino]methyl}-2,3,6-
,10b-tetrahydro-1H-benzo[f]chromene-8-carbothioamide
[0669] Starting compound: Example 42
EXAMPLE 57
N-[3-Phenyl-2-propenyl]-2-{[(cyclopropylamino)carbothioyl]amino}-2,3-dihyd-
ro-1H-4-phenalenecarbothioamide
[0670] Starting compound: Example 43
[0671] In Examples 58 to 61 the procedure is as in Example 1, but
the acid chloride is replaced by the corresponding
halogenocarboxylate.
EXAMPLE 58
Methyl N-{3-[2-(acetylamino)ethyl]benzo[b]furan-5-yl}carbamate
[0672] Starting compound: Preparation 132
[0673] Melting point=138-140.degree. C.
EXAMPLE 59
Ethyl N-(8-{2-[(2-bromoacetyl)amino]ethyl}-2-naphthyl)carbamate
[0674] Starting compound: Preparation 110
EXAMPLE 60
Methyl
N-{8-[2-(acetylamino)ethyl]-6-phenyl-2-naphthyl}carbamate
[0675] Starting compound: Preparation 129
EXAMPLE 61
Hexyl
N-{8-[2-(acetylamino)ethyl]-5,6,7,8-tetrahydro-2-naphthyl}-carbamate
[0676] Starting compound: Preparation 133
EXAMPLE 62
N-[2-(5-Methoxycarbonylbenzo[b]furan-3-yl)ethyl]acetamide
[0677] Step A: 3-Acetyl-4-hydroxybenzoic Acid
[0678] 166 mmol of aluminium chloride are added slowly to 150 ml of
nitrobenzene. 83 mmol of 4-acetylbenzoic acid are then added and
heating is carried out at 120.degree. C. for 2 hours. The mixture
is hydrolysed using 1.2 litres of ice-cold water and the aqueous
phase is acidified with 20 ml of concentrated HCl. Then, extraction
with ethyl acetate and washing with aqueous 5% sodium carbonate
solution are carried out. The aqueous phase is acidified with 6N
HCl and the precipitate obtained is dried and recrystallised.
[0679] Melting point=120-12].degree. C.
[0680] Step B: 3-(2-Bromoacetyl)-4-hydroxybenzoic Acid
[0681] The compound obtained in Step A (32.2 mmol) is dissolved in
glacial acetic acid (40 ml) and then 48.3 mmol of bromine are
added. The mixture is heated at 80.degree. C. for 2 hours and is
then hydrolysed using ice-cold water. The precipitate obtained is
filtered off, washed with water until a pH of 5-6 is obtained, and
then dried and recrystallised.
[0682] Melting point=174-175.degree. C.
[0683] Step C: Methyl 3-bromoacetyl-4-hydroxybenzoate
[0684] The compound obtained in Step B (27.4 mmol) is dissolved in
150 ml of MeOH, and 54.8 mmol of thionyl chloride are added
dropwise in the cold state. The mixture is then stirred for 1 hour
at ambient temperature and then for 2 hours at reflux. After
evaporating off the methanol and the thionyl chloride, the oily
residue is taken up in AcOEt, washed with water and then dried over
MgSO.sub.4. The solvent is evaporated off under reduced pressure
and the solid obtained is recrystallised.
[0685] Melting point=93-94.degree. C.
[0686] Step D:
5-(Methoxycarbonyl-3-benzo[b]furan-3-yl)acetonitrile
[0687] The compound obtained in Step C (15 mmol) is dissolved in 35
ml of acetone. 30 mmol of potassium carbonate are added and the
mixture is stirred for 2 hours at ambient temperature. The
precipitate formed is filtered off, washed with acetone and the
filtrate is evaporated under reduced pressure. The benzofuranone
formed is used directly in the following step: 22.5 mmol of NaH are
introduced into a 250 ml round-bottomed two-necked flask which is
placed in a bath of ice/salt and under a nitrogen atmosphere. 22.5
mmol of diethyl cyanophosphonate are added dropwise and the mixture
is then stirred for 20 minutes. The benzofuranone previously
obtained, in 140 ml of anhydrous THF, is added and the mixture is
stirred for 2 hours at ambient temperature. After hydrolysing on a
pile of ice and extracting with Et.sub.2O, the organic phase is
dried over MgSO.sub.4 and the solvent is then evaporated off under
reduced pressure. The title compound is purified by chromatography
on a silica gel column (eluant: CH.sub.2Cl.sub.2), and is then
recrystallised.
[0688] Melting point=125-126.degree. C.
[0689] Step E:
N-[2-(5-Methoxycarbonylbenzo[b]furan-3-yl)ethyl]acetamide
[0690] The 5-(methoxycarbonylbenzo[b]furan-3-yl)acetonitrile
obtained in Step D (6.46 mmol) is dissolved in acetic anhydride (30
ml) in an autoclave, and 14.4 mmol of Raney nickel are added. After
stirring overnight at 60.degree. C. and under a hydrogen pressure
of 60 bars, the catalyst is filtered off and washed with methanol.
The filtrate is evaporated to dryness and the chestnut-coloured
precipitate obtained is chromatographed on a silica gel column
using ethyl acetate as eluant and is then recrystallised.
[0691] Melting point=121-122.degree. C.
[0692] Elemental Microanalysis:
1 C H N % calculated: 64.36 5.78 5.36 % found: 64.14 5.81 5.28
EXAMPLE 63
Methyl 3-[2-(2-furoylamino)ethyl]-1-benzofuran-5-carboxylate
[0693] Step A: Methyl 3-(2-aminoethyl)-1-benzofuran-5-carboxylate
Hydrochloride
[0694] 6.57 mmol of the compound obtained in Step D of Example 62
are dissolved in 150 ml of methanol. The solution is introduced
into an autoclave and 28.8 mmol of Raney nickel are added. The
solution is saturated with ammonia, and then hydrogen is introduced
until a pressure of 60 bars is obtained. The solution is stirred
for 4 hours at a temperature of 60.degree. C. After cooling, the
catalyst is filtered off, and the methanol is then evaporated off.
The residue is purified by chromatography on a silica gel column
using a mixture of dichloromethane/methanol (7/3) and then methanol
as eluant. The amine obtained is dissolved in absolute ethanol.
Stirring is carried out in an ice bath and gaseous hydrogen
chloride is bubbled through. The hydrochloride obtained is filtered
off under suction and dried in a desiccator.
[0695] Melting point=210-211.degree. C.
[0696] Step B: Methyl
3-[2-(2-furoylamino)ethyl]-1-benzofuran-5-carboxylat- e
[0697] 1 mmol of the compound obtained in Step A is introduced into
30 ml of anhydrous CH.sub.2Cl.sub.2. The temperature is lowered
with the aid of an ice bath, and 1.5 mmol of triethylamine and then
1.5 mmol of 2-furoic acid chloride are added dropwise in
succession. The mixture is stirred for 20 minutes, and the organic
phase is then washed with water, dried over MgSO.sub.4 and
evaporated. The residue is purified by chromatography on a silica
gel column and the title product is recrystallised.
[0698] Melting point=116-118.degree. C.
[0699] Elemental Microanalysis:
2 C H N % calculated: 65.17 4.82 4.47 % found: 64.80 4.84 4.50
EXAMPLE 64
Methyl
3-{2-[(cyclopentylcarbonyl)amino]ethyl}-1-benzofuran-5-carboxylate
[0700] The procedure is as in Example 63.
[0701] Melting point=122-123.degree. C.
EXAMPLE 65
Methyl
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-1-benzofuran-5-carboxylate
[0702] The procedure is as in Example 63.
[0703] Melting point=154-155.degree. C.
EXAMPLE 66
Methyl 3-[2-(3-butenoylamino)ethyl]-1-benzofuran-5-carboxylate
[0704] Vinylacetic acid (1 mmol),
1-ethyl-3-(3-dimethylaminopropyl-3-ethyl- )carbodiimide
hydrochloride (E.D.C.) (1.1 mmol) and hydroxybenzotriazole (HOBT)
(1.1 mmol) are dissolved in dichloromethane (30 ml) in a flask
cooled to -20.degree. C. After 30 minutes, the compound obtained in
Step A of Example 63 (1 mmol), dissolved in dichloromethane (20
ml), is added dropwise. The reaction mixture is stirred for 30
minutes at -20.degree. C. and then overnight at ambient
temperature. The dichloromethane is evaporated off and the residue
is purified by chromatography on a silica gel column.
[0705] Melting point=98-100.degree. C.
EXAMPLE 67
3-[2-(Acetylamino)ethyl]-1-benzofuran-5-carboxamide
[0706] The ester (0.1 mol) obtained in Example 62, dissolved in an
aqueous 20% ammonium hydroxide solution (50 ml), is heated for 5
hours at 60.degree. C. The reaction mixture is cooled and is then
evaporated to dryness. The residue obtained is purified by
chromatography on a silica gel column.
[0707] Melting point=206-208.degree. C.
[0708] Elemental Microanalysis
3 C H N % calculated: 63.40 5.73 11.38 % found: 63.23 5.89
11.17
EXAMPLE 68
3-{2-[(Cyclopropylcarbonyl)amino]ethyl}-1-benzofuran-5-carboxamide
[0709] The same procedure is used as in Example 67.
[0710] Melting point=209-210.degree. C.
EXAMPLE 69
3-[2-(2-Furoylamino)ethyl]-1-benzofuran-5-carboxamide
[0711] The same procedure is used as in Example 67.
[0712] Melting point=110-112.degree. C.
[0713] Elemental Microanalysis:
4 C H N % calculated: 64.42 4.73 9.39 % found: 64.23 4.98 9.97
EXAMPLE 70
3-{2-[(Cyclopropylcarbonyl)amino]ethyl}-N-methyl-1-benzofuran-5-carboxamid-
e
[0714] To the ester obtained in Example 62 (1 mmol), dissolved in
methanol (40 ml) in the hot state, there is added an aqueous 40%
methylamine solution (1.6 mmol), and the mixture is refluxed for 2
hours. The reaction mixture is then cooled and the methanol is
subsequently evaporated off. The aqueous phase is extracted with
ethyl acetate, the organic phase is dried over magnesium sulphate
and the solvent is evaporated off. The residue is purified by
chromatography on a silica gel column.
[0715] Melting point=188-189.degree. C.
[0716] Elemental Microanalysis:
5 C H N % calculated: 67.11 6.34 9.78 % found: 67.00 6.34 9.77
EXAMPLE 71
3-[2-(Acetylamino)ethyl]-N-methyl-1-benzofuran-5-carboxamide
[0717] The same procedure is used as in Example 70.
[0718] Melting point=158-159.degree. C.
[0719] Elemental Microanalysis:
6 C H N % calculated: 64.59 6.20 10.76 % found: 64.27 6.13
10.44
EXAMPLE 72
3-{2-[(Cyclopentylcarbonyl)amino]ethyl}-N-methyl-1-benzofuran-5-carboxamid-
e
[0720] The same procedure is used as in Example 70.
[0721] Melting point=170-171.degree. C.
EXAMPLE 73
3-[2-(Benzoylamino)ethyl]-N-methyl-1-benzofuran-5-carboxamide
[0722] The same procedure is used as in Example 70.
EXAMPLE 74
N-{3-[2-(Acetylamino)ethyl]-1-benzofuran-5-yl}-2,2,2-trifluoroacetamide
[0723] Step A: 3-[2-(Acetylamino)ethyl]-1-benzofuran-5-carboxylic
Acid
[0724] To the ester obtained in Example 62 (2 mmol), dissolved in
methanol (90 ml), there is added aqueous 30% sodium hydroxide
solution (30 ml), and the mixture is stirred overnight. After
evaporating off the methanol, the temperature of the reaction
mixture is lowered with the aid of an ice bath and the mixture is
acidified with hydrochloric acid solution (6N). The aqueous phase
is extracted with ethyl acetate, and the organic phase is dried
over magnesium sulphate and then evaporated to dryness. The residue
obtained is recrystallised.
[0725] Melting point=210-211.degree. C.
[0726] Step B: 3-[2-(Acetylamino)ethyl]-1-benzofuran-5-carbonyl
Azide
[0727] The acid (1 mmol) obtained in Step A is dissolved in
acetone. The temperature of the reaction mixture is lowered with
the aid of an ice bath, and triethylamine (1.5 mmol) and then ethyl
chloroformate (1.5 mmol) are added. After stirring for 15 minutes,
sodium azide (1.5 mmol), previously dissolved in water (1 ml of
water per 400 mg of sodium azide), is added and stirring is again
carried out for 10 minutes. The mixture is extracted with ethyl
acetate, and the organic phase is then washed with water, dried
over magnesium sulphate and evaporated to dryness. The azide
obtained is used, without additional purification, in the following
Step.
[0728] Step C:
N-{3-[2-(Acetylamino)ethyl]-1-benzofuran-5-yl}-2,2,2-triflu-
oroacetamide
[0729] To the azide obtained in Step B (460 mg, 1.68 mmol),
dissolved in dichloromethane, there is added trifluoroacetic acid
(1.82 ml, 2.35 mmol) and stirring is carried out overnight. The
reaction mixture is washed with water and then with aqueous 10%
sodium hydrogen carbonate solution. The organic phase is dried over
magnesium sulphate and then evaporated. The residue obtained is
purified by chromatography on a silica gel column using ethyl
acetate as eluant.
[0730] Melting point=152-154.degree. C.
EXAMPLE 75
Methyl
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-1-benzofuran-5-yl-carbamate
[0731] The azide obtained in Step B of Example 74 (1 mmol) is
heated at 80.degree. C. overnight and 5 ml of MeOH and 5 ml of
toluene are added. After evaporating off the solvent, the residue
obtained is purified by chromatography on a silica gel column.
[0732] Melting point=153-155.degree. C.
[0733] Elemental Microanalysis:
7 C H N % calculated: 63.56 6.00 9.27 % found: 63.27 6.02 9.14
EXAMPLE 76
tert-Butyl 3-[2-(acetylamino)ethyl]-1-benzofuran-5-yl-carbamate
[0734] The procedure is as in Examples 74 and 75.
[0735] Melting point=146-148.degree. C.
[0736] Elemental Microanalysis:
8 C H N % calculated: 64.12 6.97 8.79 % found: 64.03 6.58 8.67
EXAMPLE 77
tert-Butyl
3-[2-(acetylamino)ethyl]-1-benzofuran-5-yl-(methyl)carbamate
[0737] To 1.98 mmol of the carbamate obtained in Example 76,
dissolved in dimethylformamide, there are added, in the cold state,
2.18 mmol of sodium hydride, and stirring is carried out for 2
hours at ambient temperature. 2.37 mmol of methyl iodide are added
to the mixture and stirring is carried out for 4 hours at ambient
temperature. The reaction mixture is hydrolysed, extracted with
ethyl acetate, and the organic phase is then washed with water and
dried over magnesium sulphate. The residue is recrystallised.
EXAMPLE 78
Methyl 3-[2-(benzoylamino)ethyl]-1-benzofuran-5-yl-carbamate
[0738] The procedure is as in Examples 74 and 75.
EXAMPLE 79
Methyl 3-[2-(isobutyrylamino)ethyl]-1-benzofuran-5-yl-carbamate
[0739] The procedure is as in Examples 74 and 75.
EXAMPLE 80
N-{2-[7-(Aminosulphonyl)-1-naphthyl]ethyl}acetamide
[0740] Step A: N-{2-[7-(Benzylthio)-1-naphthyl]ethyl}acetamide
[0741] 4.4 mmol of the compound obtained in Preparation 1 are
dissolved in 20 ml of anhydrous CH.sub.2Cl.sub.2 and placed under a
current of nitrogen. 6.5 mmol of benzylthiol are added dropwise
using a syringe and then 8.8 mmol of triflic acid are added, before
the mixture is refluxed for 24 hours. After cooling, hydrolysis is
carried out using 10% Na.sub.2CO.sub.3 solution. The organic phase
is washed with 10% sodium hydroxide solution and then with water
until the washing waters are neutral, and is then dried and
evaporated. The residue is taken up in petroleum ether and
recrystallised from a toluene/cyclohexane mixture.
[0742] Melting point=80-83.degree. C.
[0743] Step B: 8-[2-(Acetylamino)ethyl]-2-naphthalenesulphonyl
Chloride
[0744] 3 mmol of the compound obtained in Step A are crushed in a
mortar, together with 13.1 mmol of iodosobenzene and 107 g of
silica/HCl, with the aid of a pestle. Dichloromethane is added and
the silica is filtered off and washed several times with
CH.sub.2Cl.sub.2. The filtrate obtained is evaporated and the
residue is taken up in petroleum ether and then filtered.
[0745] Step C:
N-{2-[7-(Aminosulphonyl)-1-naphthyl]ethyl}acetamide
[0746] 0.8 mmol of the compound obtained in Step B is dissolved in
10 ml of CH.sub.2Cl.sub.2 and then 1.2 mmol of triethylamine are
added. The mixture is cooled with the aid of an ice bath and 1.2
mmol of ammonium hydroxide solution are added dropwise. After
stirring for 2 hours, the mixture is evaporated and the residue
obtained is recrystallised.
[0747] Melting point=194-196.degree. C.
EXAMPLE 81
N-(2-{7-[(Methylamino)sulphonyl]-1-naphthyl}ethyl)acetamide
[0748] The procedure is as in Example 80, but the ammonium
hydroxide in Step C is replaced by methylamine.
[0749] Melting point=155-156.degree. C.
[0750] By proceeding as in Example 80, but replacing, in Step A,
the compound of Preparation 1 by the appropriate substrate, and, in
Step C, the ammonium hydroxide by the appropriate amine, Examples
82 to 84 are obtained
EXAMPLE 82
N-(2-{7-[(Methylamino)sulphonyl]-1-naphthyl}ethyl)-2-furamide
[0751] Starting compound: Preparation 135
EXAMPLE 83
N-(2-{7-[(Ethylamino)sulphonyl]-1-naphthyl}ethyl)benzamide
[0752] Starting compound: Preparation 136
EXAMPLE 84
N-(2-{7-[(Methylamino)sulphonyl]-1-naphthyl)ethyl)cyclopropanecarboxamide
[0753] Starting compound: Preparation 137
EXAMPLE 85
N-(3-{5-[(Methylamino)sulphonyl]-1-benzofuran-3-yl}propyl)acetamide
[0754] Starting compound: Preparation 16
EXAMPLE 86
N-(2-{5-[(Propylamino)sulphonyl]-1-benzofuran-3-yl}ethyl)acetamide
[0755] Starting compound: Preparation 18
EXAMPLE 87
N-(2-{5-[(Cyclopropylamino)sulphonyl]-1-benzofuran-3-yl
ethyl)-benzamide
[0756] Starting compound: Preparation 138
EXAMPLE 88
N-(2-{5-[(Methylamino)sulphonyl]-1-benzofuran-3-yl}ethyl)-2-furamide
[0757] Starting compound: Preparation 139
EXAMPLE 89
N-(2-{5-[(Hexylamino)sulphonyl]-1-benzofuran-3-yl}ethyl)cyclopropanecarbox-
amide
[0758] Starting compound: Preparation 140
EXAMPLE 90
N-(2-{5-[(Methylamino)sulphonyl]-1-benzofuran-3-yl}ethyl)cyclopropanecarbo-
xamide
[0759] Starting compound: Preparation 140
EXAMPLE 91
N-(2-{2-Benzyl-5-[(methylamino)sulphonyl]-1-benzothiophen-3-yl}ethyl)-acet-
amide
[0760] Starting compound: Preparation 19
EXAMPLE 92
N-(2-{5-[(Isopropylamino)sulphonyl]-1-benzothiophen-3-yl}ethyl)-cyclopropa-
necarboxamide
[0761] Starting compound: Preparation 141
EXAMPLE 93
N-(2-{5-[(Methylamino)sulphonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}ethyl)-acet-
amide
[0762] Starting compound: Preparation 142
EXAMPLE 94
N-(2-{5-[(Methylamino)sulphonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}ethyl)-cycl-
opropanecarboxamide
[0763] Starting compound: Preparation 143
EXAMPLE 95
N-(2-{5-[(Methylamino)sulphonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}ethyl)-benz-
amide
[0764] Starting compound: Preparation 144
EXAMPLE 96
N-(2-{5-[(Methylamino)sulphonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}ethyl)-2-fu-
ramide
[0765] Starting compound: Preparation 145
[0766] Examples 97 to 105 are obtained by proceeding as in Example
1, but replacing the acid chloride by the corresponding
halogenocarboxylate.
EXAMPLE 97
Methyl
5-[(acetylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl-carbamate
[0767] Starting compound: Preparation 126
EXAMPLE 98
Methyl
3-[(acetylamino)methyl]-3,4-dihydro-2H-chromen-6-yl-carbamate
[0768] Starting compound: Preparation 124
EXAMPLE 99
Ethyl
3-[2-(acetylamino)ethyl]-2,3-dihydro-1-inden-5-yl-carbamate
[0769] Starting compound: Preparation 134
EXAMPLE 100
Methyl
3-[2-(acetylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl-carbamate
[0770] Starting compound: Preparation 148
EXAMPLE 101
Methyl
3-[2-(2-furoylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl-carbamate
[0771] Starting compound: Preparation 151
EXAMPLE 102
Methyl
3-[2-(benzoylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl-carbamate
[0772] Starting compound: Preparation 154
EXAMPLE 103
Methyl
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-1-pyrrolo[2,3-b]-pyridin-5--
yl-carbamate
[0773] Starting compound: Preparation 157
EXAMPLE 104
Methyl
3-{2-[(cyclopropylcarbonyl)amino]ethyl}-1H-pyrrolo[3,2-b]-pyridin-5-
-yl-carbamate
[0774] Starting compound: Preparation 161
EXAMPLE 105
Ethyl
3-[2-(acetylamino)ethyl]-1H-pyrrolo[3,2-b]pyridin-5-yl-carbamate
[0775] Starting compound: Preparation 165
[0776] Examples 106 to 108 are obtained by proceeding as in Example
1, starting from the appropriate substrate.
EXAMPLE 106
N-{8-[2-(Acetylamino)ethyl]-2-naphthyl}acetamide
[0777] Starting compound: Preparation 117
EXAMPLE 107
N-{2-[5-(Acetylamino)-1-benzofuran-3-yl]ethyl}cyclopropanecarboxamide
[0778] Starting compound: Preparation 168
EXAMPLE 108
N-{2-[5-(Acetylamino)-1-benzothiophen-3-yl]ethyl}benzamide
[0779] Starting compound: Preparation 172
[0780] Examples 109 to 112 are obtained by proceeding as in
Preparation 109, condensing the appropriate amine with the
intermediate acid chloride.
EXAMPLE 109
3-[2-(Acetylamino)ethyl]-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
[0781] Starting compound: Preparation 147
EXAMPLE 110
N-(2-{7-[(Methylamino)carbonyl]-1-naphthyl}ethyl)-2-furamide
[0782] Starting compound: Preparation 174
EXAMPLE 111
3-{2-[(Cyclopropylcarbonyl)amino]ethyl}-N-ethyl-1-benzofuran-5-carboxamide
[0783] Starting compound: Preparation 167
EXAMPLE 112
3-[2-(Benzoylamino)ethyl]-N-ethyl-1-benzofuran-5-carboxamide
[0784] Starting compound: Preparation 176
EXAMPLE 113
N-{8-[2-(Acetylamino)ethyl]-5,6,7,8-tetrahydro-2-naphthyl}acetamide
[0785] Step A: 7-Nitro-3,4-dihydro-1(2H)-naphthalenone
[0786] 7 mmol of 1-oxo-1,2,3,4-tetrahydronaphthalene and 5 ml of
concentrated sulphuric acid are cooled in a freezer for 30 minutes.
The reaction mixture is then placed in a bath of alcohol at
-15.degree. C. on a cooling plate. A sulphonitric mixture (1.1 ml
of sulphuric acid and 0.73 ml of nitric acid) is prepared and
brought to the temperature of the reaction mixture before being
added dropwise, avoiding any drastic heating of the mixture.
Stirring is carried out for 15 minutes and then hydrolysis on a
pile of ice is carried out. The pale yellow precipitate obtained is
washed with water until the washing waters have a neutral pH and is
then dried in a desiccator and purified on a silica gel column.
[0787] Melting point=103.7-104.3.degree. C.
[0788] Step B: 2-[7-Nitro-3,4-dihydro-1 (2
h)-naphthalenylidene]acetonitri- le
[0789] Using a 50 ml two-necked flask under a current of nitrogen
and placed in a bath of alcohol at -15.degree. C., 0.32 g of sodium
hydride is added in portions to 40 ml of THF, with magnetic
stirring, and then 1.4 g of diethyl cyanomethylphosphonate in 10 ml
of THF are added dropwise. After stirring for half an hour, when
the mixture is highly homogeneous, the flask is plunged into a
medium at -78.degree. C. (cryostat), and 1 g of the compound
obtained in Step A, dissolved in 20 ml of THF, is added dropwise.
Stirring under a current of nitrogen is carried out for 2 hours.
The reaction mixture is then brought to ambient temperature,
hydrolysed on ice and precipitated. After filtering under suction
and washing with water until the washing waters have a neutral pH,
extraction with 3 volumes of ether is carried out. The organic
phases are washed with 3 volumes of water and then dried. The grey
solid obtained is decolorised on carbon.
[0790] Melting point=98.1-98.5.degree. C.
[0791] Step C:
N-{8-[2-(Acetylamino)ethyl]-5,6,7,8-tetrahydro-2-naphthyl}a-
cetamide
[0792] 9 mmol of the compound obtained in Step B are dissolved in
acetic anhydride (100 ml) and then a small spatula of sodium
acetate is added. The mixture is introduced into an autoclave,
Raney nickel is added and autoclaving under a pressure of 40 bars
is carried out for 6 hours, with stirring at 50-60.degree. C. The
mixture is filtered and is rinsed with alcohol at 95.degree. C.;
the solvent is then evaporated off. Hydrolysis is carried out using
100 ml of distilled water and extraction with 3 volumes of
dichloromethane is carried out. The organic phase is washed with 2
volumes of water, dried over magnesium sulphate, filtered and
evaporated. Rinsing with an ether/dichloromethane mixture and
trituration in ether are carried out. The light-beige solid
obtained is recrystallised.
[0793] Melting point=127.7-128.7.degree. C.
[0794] Elemental Microanalysis:
9 C H N % calculated: 70.04 8.08 10.21 % found: 69.74 8.14
10.43
EXAMPLE 114
Methyl 8-[2-(acetylamino)ethyl]-2-naphthyl-carbamate
[0795] The procedure is as in Example 97.
[0796] Starting compound: Preparation 117
EXAMPLE 115
N-[2-(1,3-Dioxo-1,2,3,4-tetrahydrobenzo[f]quinolin-10-yl)ethyl]-2-phenylac-
etamide
[0797] A solution of the product obtained in Preparation 109 (10
mmol) in ether (160 ml) is added very slowly, using a dropper, to a
solution of malonyl dichloride (40 mmol) in ether (40 ml) and
triethylamine (2 ml). At the end of the reaction, the reaction
mixture is concentrated under reduced pressure. The residue is
dried using a vane pump and then taken up in ether. The organic
phase is washed with water, dried over magnesium sulphate,
concentrated under reduced pressure and then dried using a vane
pump. The residue is then taken up in 100 ml of
1,1,2,2-tetrachloroethane- . The resulting solution is then added
dropwise to a solution of aluminium chloride (30 mmol) in 50 ml of
the same solvent under nitrogen. The mixture is heated at
60.degree. C. until the reaction has ceased; the reaction mixture
is then poured into a mixture of ice (20 g) and concentrated HCl (1
ml) and is stirred for one hour. The aqueous phase is extracted
twice with chloroform and then the combined organic phases are
dried over magnesium sulphate and concentrated under reduced
pressure. The residue is chromatographed on silica gel to yield the
title product.
[0798] In Examples 116 to 120 the procedure is as in Example 115,
starting from appropriate substrates.
EXAMPLE 116
N-Cyclohexyl-4-(1,3-dioxo-1,2,3,4-tetrahydrobenzo[f]quinolin-10-yl)-butana-
mide
[0799] Starting compound: Preparation 112
EXAMPLE 117
N-[2-(7-Benzoyl-1,2-dioxo-2,3-dihydro-1H-benzo[e]indol-9-yl)ethyl]-N'-prop-
ylurea
[0800] Starting compound: Preparation 115
EXAMPLE 118
N-Methyl-4-(7,9-dioxo-6,7,8,9-tetrahydrofuro[3,2-f]quinolin-1-yl)-butanami-
de
[0801] Starting compound: Preparation 119
EXAMPLE 119
N-{2-[2-(4-Fluorobenzyl)-3-methyl-7,8-dioxo-3,6,7,8-tetrahydro-dipyrrolo[2-
,3-b:3,2-d]pyridin-1-yl]ethyl}acetamide
[0802] Starting compound: Preparation 122
EXAMPLE 120
N-[(8,10-Dioxo-2,3,7,8,9,10-hexahydro-1H-pyrano[3,2-f]quinolin-2-yl)-methy-
l]acetamide
[0803] Starting compound: Preparation 124
EXAMPLE 121
N-[2-(3-Oxo-1,2,3,4-tetrahydrobenzo[f]quinolin-10-yl)ethyl]-2-phenylacetam-
ide
[0804] The product of Example 115 (3 mmol) is dissolved in acetic
acid (70 ml). After several purges with argon, 10%
palladium-on-carbon (600 mg) is added and the mixture is placed
under a hydrogen atmosphere. Stirring is carried out at ambient
temperature until the end of the reaction (monitored by TLC) and
the palladium is filtered off over Celite. The acetic acid is
evaporated off to dryness and the residue is chromatographed on
silica gel to yield the title product.
[0805] In Examples 122 to 126 the procedure is as in Example 121,
starting from appropriate substrates.
EXAMPLE 122
N-Cyclohexyl-4-(3-oxo-1,2,3,4-tetrahydrobenzo[f]quinolin-10-yl)-butanamide
[0806] Starting compound: Example 116
EXAMPLE 123
N-[2-(7-Benzoyl-2-oxo-2,3-dihydro-1-benzo[e]indol-9-yl)ethyl]-N'-propylure-
a
[0807] Starting compound: Example 117
EXAMPLE 124
N-Methyl-4-(9-oxo-6,7,8,9-tetrahydrofuro[3,2-]quinolin-1-yl)-butanamide
[0808] Starting compound: Example 118
EXAMPLE 125
N-{2-12-(4-Fluorobenzyl)-3-methyl-8-oxo-3,6,7,8-tetrahydropyrrolo-[2,3-b:3-
,2-d]pyridin-1-yl ethyl}acetamide
[0809] Starting compound: Example 119
EXAMPLE 126
N-[(8-Oxo-2,3,7,8,9,10-hexahydro-1-pyrano[3,2-f]quinolin-2-yl)-methyl]acet-
amide
[0810] Starting compound: Example 120
EXAMPLE 127
N-[2-(4-Oxo-3,4-dihydrobenzo[f]isoquinolin-10-yl)ethyl]-1-cyclohexanecarbo-
xamide
[0811] The product of Example 33 (10 mmol) and triethylene glycol
are introduced into a two-necked flask. Heating is carried out at
160-170.degree. C., under nitrogen and with stirring, for five
hours. The reaction mixture is poured into ice-cold water and is
extracted with ethyl acetate. The organic phase is washed with
water and dried over calcium chloride. After filtration, the
organic phase is concentrated under reduced pressure. The residue
is chromatographed on silica gel to yield the title product.
[0812] In Examples 128 to 132, the procedure is as in Example 127,
starting from appropriate substrates.
EXAMPLE 128
N-[2-(2-Benzyl-7-isopropyl-6-oxo-6,7-dihydrothieno[3,2-f]isoquinolin-1-yl)-
ethyl]acetamide
[0813] Starting compound: Example 37
EXAMPLE 129
N-[2-(3-Cyclohexyl-4-oxo-3,8,9,10-tetrahydro-4H-thiopyrano[3,2-f]-isoquino-
lin-10-yl)ethyl]acetamide
[0814] Starting compound: Example 40
EXAMPLE 130
N-[2-(4-Oxo-3,4-dihydrobenzo[f]isoquinolin-10-yl)ethyl]-2-bromoacetamide
[0815] Starting compound: Example 46
EXAMPLE 131
N-[2-(2-Benzyl-6-oxo-6,7-dihydrofuro[3,2-f]isoquinolin-1-yl)ethyl]-1-cyclo-
propanecarboxamide
[0816] Starting compound: Example 49
EXAMPLE 132
N-[(9-Isopropyl-7-oxo-3-phenyl-3,7,8,9-tetrahydrochromeno[6,5-c]-azepin-2--
yl)methyl]butanamide
[0817] Starting compound: Example 50
EXAMPLE 133
N-[2-(1,4-Dioxo-1,3,4,8,9,10-hexahydro-2H-pyrano[3,2-f]isoquinolin-10-yl)e-
thyl]-2-phenylacetamide
[0818] Step A:
2-{[(4-{2-[(2-Phenylacetyl)amino]ethyl}-3,4-dihydro-2H-chro-
men-6-yl)-carbonyl]amino}acetic Acid
[0819] A 0.5N aqueous solution of K.sub.2CO.sub.3 (10 ml) is added
to the product obtained in Example 39 (4 mmol) dissolved in
methanol (10 ml). When the reaction has ceased, the solution is
acidified to pH 6-7 using 1N hydrochloric acid solution. The
reaction mixture is extracted with dichloromethane. The organic
phase is washed with water, dried over magnesium sulphate and
concentrated under reduced pressure. The residue is chromatographed
on silica gel to yield the title product.
[0820] Step B:
2-{[(4-{2-[(2-Phenylacetyl)amino]ethyl}-3,4-dihydro-2H-chro-
men-6-yl)-carbonyl]amino}acetyl Chloride
[0821] The product obtained in Step A (3 mmol), dissolved in
thionyl chloride, is stirred at 60.degree. C. under a current of
nitrogen for one hour. The thionyl chloride is evaporated off under
reduced pressure and the residue is dried with the aid of a vane
pump to yield the title product.
[0822] Step C:
N-[2-(1,4-Dioxo-1,3,4,8,9,10-hexahydro-2H-pyrano[3,2-f]isoq-
uinolin-10-yl)-ethyl]-2-phenylacetamide
[0823] The product obtained in Step B (3 mmol), dissolved in
1,1,2,2-tetrachloroethane (30 ml), is added dropwise to a solution
of aluminium chloride (10 mmol) in the same solvent (20 ml) under
nitrogen. The reaction mixture is heated at 60.degree. C., with
stirring, until the reaction has ceased. The solution is then
poured into a mixture of ice (10 g)/concentrated HCl (0.3 ml) and
stirring is carried out for one hour. The aqueous phase is
extracted twice with chloroform; the combined organic phases are
then dried over magnesium sulphate and concentrated under reduced
pressure. The residue is chromatographed on silica gel to yield the
title product.
[0824] In Examples 134 to 135 the procedure is as in Example 133,
starting from appropriate reactants.
EXAMPLE 134
N-[2-(1,4-Dioxo-8-naphthyl-1,2,3,4-tetrahydro[f]isoquinolin-10-yl)-ethyl]h-
eptanamide
[0825] Starting compound: Example 45
EXAMPLE 135
N-{2-[8-(Cyclopropylmethyl)-1,4-dioxo-1,2,3,4-tetrahydrobenzo[f]-isoquinol-
in-10-yl]ethyl}acetamide
[0826] Starting compound: Example 48
[0827] In Examples 136 to 138 the procedure is as in Example 122,
starting from appropriate substrates.
EXAMPLE 136
N-[2-(4-Oxo-1,3,4,8,9,10-hexahydro-2H-pyrano[3,2-f]isoquinolin-10-yl)-ethy-
l]-2-phenylacetamide
[0828] Starting compound: Example 133
EXAMPLE 137
N-[2-(4-Oxo-8-naphthyl-1,2,3,4-tetrahydrobenzo[f]isoquinolin-10-yl)-ethyl]-
heptanamide
[0829] Starting compound: Example 134
EXAMPLE 138
N-{2-[8-(Cyclopropylmethyl)-4-oxo-1,2,3,4-tetrahydrobenzo[f]-isoquinolin-1-
0-yl]ethyl}acetamide
[0830] Starting compound: Example 135
EXAMPLE 139
N-[2-(4-Thioxo-3,4-dihydrobenzo[isoquinolin-10-yl)ethyl]-1-cyclohexanecarb-
othioamide
[0831] The product obtained in Example 127 is treated with
Lawesson's reagent to yield the title compound. Examples 140 to 142
are obtained by proceeding as in Example 139.
EXAMPLE 140
N-[2-(3-Cyclohexyl-4-thioxo-3,8,9,10-tetrahydro-4H-thiopyrano[3,2-f]-isoqu-
inolin-10-yl)ethyl]acetamide
[0832] Starting compound: Example 129
EXAMPLE 141
N-[2-(1,4-Dithioxo-1,3,4,8,9,10-hexahydro-2H-pyrano[3,2-f]isoquinolin-10-y-
l)ethyl]-2-phenylethanethioamide
[0833] Starting compound: Example 133
EXAMPLE 142
N-{2-[8-(Cyclopropylmethyl)-4-thioxo-1,2,3,4-tetrahydrobenzo[f]-isoquinoli-
n-10-yl]ethyl}ethanethioamide
[0834] Starting compound: Example 138
EXAMPLE 143
N-Cyclohexyl-4-(1-hydroxy-3-oxo-1,2,3,4-tetrahydrobenzo[f]quinolin-10-yl)b-
utanamide
[0835] A solution of the product obtained in Example 116 (2 mmol)
dissolved in methanol (10 ml) is added dropwise to a suspension of
sodium hydride (2.2 mmol) in methanol (50 ml) at -40.degree. C.
Stirring is carried out until the starting compound has completely
disappeared (about 3 hours). At the end of the reaction, the
solution is poured into water (30 ml). The reaction mixture is
concentrated under reduced pressure to a volume of about 30 ml and
is then extracted with ethyl acetate. The aqueous phase is washed
with water, dried over magnesium sulphate and concentrated under
reduced pressure. The residue is chromatographed on silica gel to
yield the title product.
[0836] In Examples 144 and 145, the procedure is as in Example
143.
EXAMPLE 144
N-[(10-Hydroxy-8-oxo-2,3,7,8,9,10-hexahydro-1-pyrano[3,2-f]quinolin-2-yl)m-
ethyl]acetamide
[0837] Starting compound: Example 120
EXAMPLE 145
N-[2-(1-Hydroxy-4-methyl-1,2,3,4-tetrahydrobenzo[f]quinolin-10-yl)ethyl]-2-
-phenylacetamide
[0838] Starting compound: Example 133
EXAMPLE 146
Methyl 3-[2-(2-furoylamino)ethyl]-1-benzofuran-5-yl-carbamate
[0839] The procedure is as in Examples 74 and 75.
EXAMPLE 147
Methyl
3-{2-[(cyclopentylcarbonyl)amino]ethyl}-1-benzofuran-5-yl-carbamate
[0840] The procedure is as in Examples 74 and 75.
EXAMPLE 148
Methyl 3-[2-(benzoylamino)ethyl]-1-benzofuran-5-carboxylate
[0841] The procedure is as in Example 63.
EXAMPLE 149
Methyl 3-[2-(isobutylamino)ethyl]-1-benzofuran-5-carboxylate
[0842] The procedure is as in Example 63.
EXAMPLE 150
3-[2-(Benzoylamino)ethyl]-1-benzofuran-5-carboxamide
[0843] The procedure is as in Example 67.
EXAMPLE 151
Methyl 8-[2-(3-butenoylamino)ethyl]-2-naphthyl-carbamate
[0844] The procedure is as in Examples 74 and 75.
EXAMPLE 152
N-18-12-(Acetylamino)ethyl]-2-naphthyl}-4-fluorobenzamide
[0845] The procedure is as in Example 1, starting from the compound
obtained in Preparation 117.
EXAMPLE 153
Ethyl 3-[2-(benzoylamino)ethyl]-1-benzofuran-5-carboxylate
[0846] The procedure is as in Example 62.
Pharmacological Study
EXAMPLE A
Acute Toxicity Study
[0847] Acute toxicity was evaluated after oral administration to
groups each comprising 8 mice (26.+-.2 grams). The animals were
observed at regular intervals during the course of the first day,
and daily for the two weeks following treatment. The LD.sub.50
(dose that causes the death of 50% of the animals) was evaluated
and demonstrated the low toxicity of the compounds of the
invention.
EXAMPLE B
Melatonin Receptor Binding Study on Pars Tuberalis Cells of
Sheep
[0848] Melatonin receptor binding studies of the compounds of the
invention were carried out according to conventional techniques on
pars tuberalis cells of sheep. The pars tuberalis of the
adenohypophysis is in fact characterised in mammals by a high
density of melatonin receptors (Journal of Neuroendocrinology, 1,
pp. 1-4, 1989).
[0849] Protocol
[0850] 1) Sheep pars tuberalis membranes are prepared and used as
target tissue in saturation experiments to determine the binding
capacities and affinities for 2-[.sup.125I]-iodomelatonin.
[0851] 2) Sheep pars tuberalis membranes are used as target tissue
in competitive binding experiments using the various test compounds
in comparison with melatonin.
[0852] Each experiment is carried out in triplicate and a range of
different concentrations is tested for each compound. The results
enable the determination, after statistical processing, of the
binding affinities of the compound tested.
[0853] Results
[0854] The compounds of the invention appear to have a strong
affinity for melatonin receptors.
EXAMPLE C
1. Melatonin mt.sub.1 and MT.sub.2 Receptor Binding Study
[0855] The mt.sub.1 or MT.sub.2 receptor binding experiments are
carried out using 2-[.sup.125I]-melatonin as reference radioligand.
The radioactivity retained is determined using a liquid
scintillation counter.
[0856] Competitive binding experiments are then carried out in
triplicate using the various test compounds. A range of different
concentrations is tested for each compound. The results enable the
binding affinities of the compounds tested (IC.sub.50) to be
determined.
[0857] 2. Study of Binding to MT.sub.3 Melatonin Binding Sites
[0858] The MT.sub.3 site binding experiments are carried out on
hamster brain membranes using 2-[.sup.125I]-melatonin as reference
radioligand. The membranes are incubated for 30 minutes with the
2-[.sup.125I]-melatonin at a temperature of 4.degree. C. and at
different concentrations of the test compounds. After incubation,
the membranes are quickly filtered and then washed with cold buffer
using a filtration system. The radioactivity fixed is measured
using a scintillation counter. The IC.sub.50 values (concentration
inhibiting specific binding by 50%) are calculated from competition
curves according to a non-linear regression model.
[0859] The IC.sub.50 values found for the compounds of the
invention demonstrate binding to one or other of the receptor
sub-types, the values being .ltoreq.10 .mu.M.
EXAMPLE D
Action of the Compounds of the Invention on the Circadian Rhythms
of Locomotive Activity of the Rat
[0860] The involvement of melatonin in influencing, by day/night
alternation, the majority of physiological, biochemical and
behavioural circadian rhythms has made it possible to establish a
pharmacological model for research into melatoninergic ligands.
[0861] The effects of the molecules are tested on numerous
parameters and, in particular, on the circadian rhythms of
locomotive activity, which are a reliable indicator of the
endogenous circadian clock.
[0862] In this study, the effects of such molecules on a particular
experimental model, namely the rat placed in temporal isolation
(permanent darkness), is evaluated.
[0863] Experimental protocol
[0864] One-month-old male rats are subjected, as soon as they
arrive at the laboratory, to a light cycle of 12 hours' light per
24 hours (LD 12:12).
[0865] After 2 to 3 weeks' adaptation, they are placed in cages
fitted with a wheel connected to a recording system, in order to
detect the phases of locomotive activity and thus monitor the
nychthemeral rhythms (LD) or circadian rhythms (DD).
[0866] As soon as the rhythms recorded show a stable pattern during
the light cycle LD 12:12, the rats are placed in permanent darkness
(DD).
[0867] Two to three weeks later, when the free course (rhythm
reflecting that of the endogenous clock) is clearly established,
the rats are given a daily administration of the molecule to be
tested.
[0868] The observations are made by means of visualisation of the
rhythms of activity:
[0869] influence on the rhythms of activity by the light/dark
cycle,
[0870] disappearance of the influence on the rhythms in permanent
darkness,
[0871] influence on the activity by the daily administration of the
molecule; transitory or durable effect.
[0872] A software package makes it possible:
[0873] to measure the duration and intensity of the activity, the
period of the rhythm of the animals during free course and during
treatment,
[0874] possibly to demonstrate by spectral analysis the existence
of circadian and non-circadian (for example ultradian)
components.
[0875] Results
[0876] The compounds of the invention clearly appear to allow
powerful action on the circadian rhythm via the melatoninergic
system.
EXAMPLE E
Light/Dark Cages Test
[0877] The compounds of the invention are tested on a behavioural
model, the light/dark cages test, which allows the anxiolytic
activity of the compounds to be demonstrated.
[0878] The apparatus consists of two polyvinyl boxes covered with
Plexiglass. One of the boxes is in darkness. A lamp is placed above
the other box, yielding a light intensity of approximately 4000 lux
in the centre of the box. An opaque plastic tunnel separates the
light box from the dark box. The animals are tested individually
for a session of 5 minutes. The floor of each box is cleaned
between each session. At the start of each test, the mouse is
placed in the tunnel, facing the dark box. The time spent by the
mouse in the illuminated box and the number of passages through the
tunnel are recorded after the first entry into the dark box.
[0879] After administration of the compounds 30 minutes before the
start of the test, the compounds of the invention significantly
increase the time spent in the illuminated cage and the number of
passages through the tunnel, which demonstrates the anxiolytic
activity of the compounds of the invention.
EXAMPLE F
Activity of Compounds of the Invention on the Caudal Artery of the
Rat
[0880] The compounds of the invention were tested in vitro on the
caudal artery of the rat. Melatoninergic receptors are present in
those vessels, thus providing a relevant pharmacological model for
studying melatoninergic ligand activity. The stimulation of the
receptors can cause either vasoconstriction or dilation depending
on the arterial segment studied.
[0881] Protocol
[0882] One-month old rats are accustomed to a light/dark cycle of
12 h/12 h during a period of 2 to 3 weeks.
[0883] After sacrifice, the caudal artery is isolated and
maintained in a highly oxygenated medium. The arteries are then
cannulated at both ends, suspended vertically in an organ chamber
in a suitable medium and perfused via their proximal end. The
pressure changes in the perfusion flow enable evaluation of the
vasoconstrictive or vasodilatory effect of the compounds.
[0884] The activity of the compounds is evaluated on segments that
have been pre-contracted by phenylephrine (1 .mu.M). A
concentration/response curve is determined non-cumulatively by the
addition of a concentration of the test compound to the
pre-contracted segment. When the observed effect reaches
equilibrium, the medium is changed and the preparation is left for
20 minutes before the addition of the same concentration of
phenylephrine and a further concentration of the test compound.
[0885] Results
[0886] The compounds of the invention significantly modify the
diameter of caudal arteries pre-constricted by phenylephrine.
EXAMPLE G
Pharmaceutical Composition: Tablets
[0887]
10 1000 tablets each comprising 5 mg of methyl 3- 5 g
{2-[(cyclopropylcarbonyl)- amino]ethyl}-1-benzofuran-5-yl-c-
arbamate (Example 75) wheat starch 20 g maize starch 20 g lactose
30 g magnesium stearate 2 g silica 1 g hydroxypropyl cellulose 2
g
* * * * *